1
|
Gragnaniello V, Pijnappel PW, Burlina AP, In 't Groen SL, Gueraldi D, Cazzorla C, Maines E, Polo G, Salviati L, Di Salvo G, Burlina AB. Newborn screening for Pompe disease in Italy: Long-term results and future challenges. Mol Genet Metab Rep 2022; 33:100929. [PMID: 36310651 PMCID: PMC9597184 DOI: 10.1016/j.ymgmr.2022.100929] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Accepted: 10/14/2022] [Indexed: 11/06/2022] Open
Abstract
Pompe disease (PD) is a progressive neuromuscular disorder caused by a lysosomal acid α-glucosidase (GAA) deficiency. Enzymatic replacement therapy is available, but early diagnosis by newborn screening (NBS) is essential for early treatment and better outcomes, especially with more severe forms. We present results from 7 years of NBS for PD and the management of infantile-onset (IOPD) and late-onset (LOPD) patients, during which we sought candidate predictive parameters of phenotype severity at baseline and during follow-up. We used a tandem mass spectrometry assay for α-glucosidase activity to screen 206,741 newborns and identified 39 positive neonates (0.019%). Eleven had two pathogenic variants of the GAA gene (3 IOPD, 8 LOPD); six carried variants of uncertain significance (VUS). IOPD patients were treated promptly and had good outcomes. LOPD and infants with VUS were followed; all were asymptomatic at the last visit (mean age 3.4 years, range 0.5–5.5). Urinary glucose tetrasaccharide was a useful and biomarker for rapidly differentiating IOPD from LOPD and monitoring response to therapy during follow-up. Our study, the largest reported to date in Europe, presents data from longstanding NBS for PD, revealing an incidence in North East Italy of 1/18,795 (IOPD 1/68,914; LOPD 1/25,843), and the absence of mortality in IOPD treated from birth. In LOPD, rigorous long-term follow-up is needed to evaluate the best time to start therapy. The high pseudodeficiency frequency, ethical issues with early LOPD diagnosis, and difficulty predicting phenotypes based on biochemical parameters and genotypes, especially in LOPD, need further study.
Collapse
Key Words
- Acid α-glucosidase
- CLIR, Collaborative Laboratory Integrated Reports
- CRIM, cross-reactive immunological material
- DBS, dried blood spot
- DMF, digital microfluidics
- ECG, electrocardiogram
- EF, ejection fraction
- EMG, electromyography
- ERT, enzyme replacement therapy
- Enzyme replacement therapy
- GAA, acid α-glucosidase
- GMFM-88, Gross Motor Function Measure
- Glc4, glucose tetrasaccharide
- IOPD, infantile-onset Pompe disease
- ITI, immunotolerance induction
- LOPD, late-onset Pompe disease
- LVMI, left ventricular max index
- MFM-20, motor function measurement
- MRC, Medical Research Council Scale
- MRI, magnetic resonance imaging
- MS/MS, tandem mass spectrometry
- NBS, newborn screening
- Newborn screening
- PBMC, peripheral blood mononuclear cells
- PD, Pompe disease
- PPV, positive predictive value
- Pompe disease
- RUSP, Recommended Uniform Screening Panel
- Tandem mass-spectrometry
- Urinary tetrasaccharide
- VUS, variants of uncertain significance.
- nv, normal values
- rhGAA, recombinant human GAA
Collapse
Affiliation(s)
- Vincenza Gragnaniello
- Division of Inherited Metabolic Diseases, Department of Diagnostic Services, University Hospital, Padua, Italy
| | - Pim W.W.M. Pijnappel
- Department of Pediatrics, Erasmus University Medical Center, Rotterdam, the Netherlands
- Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands
- Center for Lysosomal and Metabolic Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands
| | | | - Stijn L.M. In 't Groen
- Department of Pediatrics, Erasmus University Medical Center, Rotterdam, the Netherlands
- Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands
- Center for Lysosomal and Metabolic Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - Daniela Gueraldi
- Division of Inherited Metabolic Diseases, Department of Diagnostic Services, University Hospital, Padua, Italy
| | - Chiara Cazzorla
- Division of Inherited Metabolic Diseases, Department of Diagnostic Services, University Hospital, Padua, Italy
| | - Evelina Maines
- Division of Pediatrics, S. Chiara General Hospital, Trento, Italy
| | - Giulia Polo
- Division of Inherited Metabolic Diseases, Department of Diagnostic Services, University Hospital, Padua, Italy
| | - Leonardo Salviati
- Clinical Genetics Unit, Department of Women's and Children's Health, and Myology Center, University of Padova, Padova, Italy
| | - Giovanni Di Salvo
- Division of Paediatric Cardiology, Department of Women's and Children's Health, University Hospital Padua, Padua, Italy
| | - Alberto B. Burlina
- Division of Inherited Metabolic Diseases, Department of Diagnostic Services, University Hospital, Padua, Italy
- Corresponding author at: Division of Inherited Metabolic Diseases, Department of Diagnostic Services, University Hospital, via Orus 2/c, 35129 Padua, Italy.
| |
Collapse
|
2
|
Meshitsuka S, Ninomiya R, Nagamura-Inoue T, Okada T, Futami M, Tojo A. CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy. Regen Ther 2022; 21:442-52. [PMID: 36313397 DOI: 10.1016/j.reth.2022.09.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2022] [Revised: 09/14/2022] [Accepted: 09/25/2022] [Indexed: 11/06/2022] Open
Abstract
Introduction Mesenchymal stromal cells (MSCs) hold the potential for application as cellular therapy products; however, there are many problems that need to be addressed before the use in clinical settings, these include the heterogeneity of MSCs, scalability in MSC production, timing and techniques for MSC administration, and engraftment efficiency and persistency of administered MSCs. In this study, problems regarding immune rejection caused by human leukocyte antigen (HLA) mismatches were addressed. Methods Umbilical cord-derived MSCs (UC-MSCs) were gene-edited to avoid allogeneic immunity. The HLA class I expression was abrogated by the knock-out of the beta-2-microglobulin (B2M) gene; instead, the B2M-HLA-G fusion gene was knocked-in using the CRISPR/Cas9 system in combination with adeno-associated virus (AAV). Results Cell surface markers on gene-edited UC-MSCs were not different from those on primary UC-MSCs. The gene-edited UC-MSCs also retained the potential to differentiate into adipocytes, osteoblasts, and chondrocytes. B2M gene knock-out alone protected cells from allogeneic T cell immune responses but were vulnerable to NK cells. B2M gene knock-out in combination with B2M-HLA-G knock-in protected cells from both T cells and NK cells. The B2M-HLA-G knock-in MSCs retained a good immunosuppressive ability and the addition of these cells into the mixing lymphocyte reaction showed a significant inhibition of T cell proliferation. Conclusions The results of this study demonstrated the possibility that the CRISPR/Cas9 system combined with AAV can be used to effectively disrupt/introduce any gene into UC-MSCs. Our findings suggest that the gene-edited cell line produced here using this method may have a higher ability to escape the cytotoxic activity of immune cells than primary cells, thereby being more advantageous for long-term graft survival. The CRISPR/Cas9 system with AAV1/2 could knock in/out efficiently in UC-MSCs. B2M-HLA-G fusion gene was successfully introduced and expressed to the cell surface. Gene edited UC-MSCs were capable of evading allogeneic immune responses.
Collapse
Key Words
- AAV
- AAV, adeno-associated virus
- Allogenic rejection
- CRISPR/Cas9
- FASL, FAS ligand
- GVHD, graft versus host disease
- HLA, human leukocyte antigen
- HLA-G
- HR, homologous recombination
- HSC, hematopoietic stem cells
- ITR, inverted terminal repeats
- KIR, killer-cell immunoglobulin-like receptors
- LILR, leukocyte immunoglobulin-like receptors
- MLR, mixed lymphocyte reaction
- MSC, mesenchymal stromal cells
- PBMC, peripheral blood mononuclear cells
- PS, penicillin–streptomycin
- SD, standard deviation
- UC-MSCs
Collapse
|
3
|
Poller W, Escher F, Haas J, Heidecker B, Schultheiss HP, Attanasio P, Skurk C, Haghikia A, Meder B, Klaassen S. Missense Variant E1295K of Sodium Channel SCN5A Associated With Recurrent Ventricular Fibrillation and Myocardial Inflammation. JACC Case Rep 2022; 4:280-286. [PMID: 35257103 PMCID: PMC8897185 DOI: 10.1016/j.jaccas.2022.01.016] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Accepted: 01/14/2022] [Indexed: 12/21/2022]
Abstract
SCN5A was considered an exclusively cardiac expressed ion channel but discovered to also act as a novel innate immune sensor. We report on a young SCN5A variant carrier with recurrent ventricular fibrillation and massive myocardial inflammation whose peculiar clinical course is highly suggestive of such a dual role of SCN5A. (Level of Difficulty: Advanced.)
Collapse
Key Words
- CAD, coronary artery disease
- CMP, cardiomyopathy
- DCM, dilated cardiomyopathy
- EMB, endomyocardial biopsy
- LV, left ventricle
- LVEF, left ventricular ejection fraction
- LVMi, left ventricular mass index
- MRI, magnetic resonance imaging
- PBMC, peripheral blood mononuclear cells
- PCR, polymerase chain reaction
- RT-PCR, reverse transcriptase polymerase chain reaction
- SCD, sudden cardiac death
- SCN5A, sodium voltage-gated channel alpha subunit 5
- VES, ventricular extrasystole
- VF, ventricular fibrillation
- VT, ventricular tachycardia
- inflammation
- innate immune response
- ion channel diseases
- ion channel functions
- variant screening
Collapse
Affiliation(s)
- Wolfgang Poller
- Department of Cardiology, Campus Benjamin Franklin, Charité Centrum 11, Berlin, Germany.,Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Berlin, Germany.,German Center for Cardiovascular Research (DZHK), Berlin, Germany
| | - Felicitas Escher
- Department of Cardiology, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.,Institute for Clinical Diagnostics and Therapy (IKDT), Berlin, Germany
| | - Jan Haas
- Department of Cardiology, University Hospital Heidelberg, Mannheim, Germany.,German Center for Cardiovascular Research (DZHK), Heidelberg, Germany
| | - Bettina Heidecker
- Department of Cardiology, Campus Benjamin Franklin, Charité Centrum 11, Berlin, Germany.,German Center for Cardiovascular Research (DZHK), Berlin, Germany
| | | | - Philipp Attanasio
- Department of Cardiology, Campus Benjamin Franklin, Charité Centrum 11, Berlin, Germany.,German Center for Cardiovascular Research (DZHK), Berlin, Germany
| | - Carsten Skurk
- Department of Cardiology, Campus Benjamin Franklin, Charité Centrum 11, Berlin, Germany.,German Center for Cardiovascular Research (DZHK), Berlin, Germany
| | - Arash Haghikia
- Department of Cardiology, Campus Benjamin Franklin, Charité Centrum 11, Berlin, Germany.,German Center for Cardiovascular Research (DZHK), Berlin, Germany.,Berlin Institute of Health, Berlin, Germany
| | - Benjamin Meder
- Department of Cardiology, University Hospital Heidelberg, Mannheim, Germany.,German Center for Cardiovascular Research (DZHK), Heidelberg, Germany.,Department of Genetics, Stanford University School of Medicine, Palo Alto, California, USA
| | - Sabine Klaassen
- German Center for Cardiovascular Research (DZHK), Berlin, Germany.,Department of Pediatric Cardiology, Charité-Universitätsmedizen, Berlin, Germany.,Experimental and Clinical Research Center (ECRC), Berlin, Germany
| |
Collapse
|
4
|
Van Anh TT, Mostafa A, Rao Z, Pace S, Schwaiger S, Kretzer C, Temml V, Giesel C, Jordan PM, Bilancia R, Weinigel C, Rummler S, Waltenberger B, Hung T, Rossi A, Stuppner H, Werz O, Koeberle A. From Vietnamese plants to a biflavonoid that relieves inflammation by triggering the lipid mediator class switch to resolution. Acta Pharm Sin B 2021; 11:1629-1647. [PMID: 34221873 PMCID: PMC8245855 DOI: 10.1016/j.apsb.2021.04.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Revised: 04/07/2021] [Accepted: 04/07/2021] [Indexed: 12/15/2022] Open
Abstract
Chronic inflammation results from excessive pro-inflammatory signaling and the failure to resolve the inflammatory reaction. Lipid mediators orchestrate both the initiation and resolution of inflammation. Switching from pro-inflammatory to pro-resolving lipid mediator biosynthesis is considered as efficient strategy to relieve chronic inflammation, though drug candidates exhibiting such features are unknown. Starting from a library of Vietnamese medical plant extracts, we identified isomers of the biflavanoid 8-methylsocotrin-4'-ol from Dracaena cambodiana, which limit inflammation by targeting 5-lipoxygenase and switching the lipid mediator profile from leukotrienes to specialized pro-resolving mediators (SPM). Elucidation of the absolute configurations of 8-methylsocotrin-4'-ol revealed the 2S,γS-isomer being most active, and molecular docking studies suggest that the compound binds to an allosteric site between the 5-lipoxygenase subdomains. We identified additional subordinate targets within lipid mediator biosynthesis, including microsomal prostaglandin E2 synthase-1. Leukotriene production is efficiently suppressed in activated human neutrophils, macrophages, and blood, while the induction of SPM biosynthesis is restricted to M2 macrophages. The shift from leukotrienes to SPM was also evident in mouse peritonitis in vivo and accompanied by a substantial decrease in immune cell infiltration. In summary, we disclose a promising drug candidate that combines potent 5-lipoxygenase inhibition with the favorable reprogramming of lipid mediator profiles.
Collapse
Key Words
- 12-HHT, 12(S)-hydroxy-5-cis-8,10-trans-heptadecatrienoic acid
- 5-H(p)ETE, 5-hydro(pero)xy-eicosatetraenoic acid
- COX, cyclooxygenase
- DAD, diode array detector
- DPPH, 2,2-diphenyl-1-picrylhydrazyl
- ECD, electronic circular dichroism
- ESI, electrospray ionization
- FCS, fetal calf serum
- HPLC, high performance liquid chromatography
- HR, high resolution
- IFN, interferon
- IL, interleukin
- Inflammation
- LOX, lipoxygenase
- LT, leukotriene
- LTC4S, leukotriene C4 synthase
- Lipid mediator
- Lipidomics
- Lipoxygenase
- MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- MaR, maresin
- Natural product
- PBMC, peripheral blood mononuclear cells
- PD, protectin
- PG, prostaglandin
- PMNL, polymorphonuclear neutrophils
- RP, reversed phase
- Resolution
- Rv, resolvin
- SPE, solid phase extraction
- SPM, specialized pro-resolving mediators
- TX, thromboxane
- UPLC‒MS/MS, ultra-performance liquid chromatography–tandem mass spectrometry
- mPGES-1, microsomal prostaglandin E2 synthase 1
- sEH, soluble epoxide hydrolase
Collapse
Affiliation(s)
- Tran Thi Van Anh
- Institute of Pharmacy/Pharmacognosy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck 6020, Austria
- Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City 700000, Viet Nam
| | - Alilou Mostafa
- Institute of Pharmacy/Pharmacognosy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck 6020, Austria
| | - Zhigang Rao
- Michael Popp Institute and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck 6020, Austria
| | - Simona Pace
- Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, Jena 07743, Germany
| | - Stefan Schwaiger
- Institute of Pharmacy/Pharmacognosy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck 6020, Austria
| | - Christian Kretzer
- Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, Jena 07743, Germany
| | - Veronika Temml
- Institute of Pharmacy/Pharmacognosy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck 6020, Austria
- Institute of Pharmacy, Department of Pharmaceutical and Medicinal Chemistry, Paracelsus Medical University Salzburg, Salzburg 5020, Austria
| | - Carsten Giesel
- Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, Jena 07743, Germany
| | - Paul M. Jordan
- Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, Jena 07743, Germany
| | - Rossella Bilancia
- Department of Pharmacy, School of Medicine, University of Naples Federico II, Naples 80131, Italy
| | - Christina Weinigel
- Institute of Transfusion Medicine, University Hospital Jena, Jena 07747, Germany
| | - Silke Rummler
- Institute of Transfusion Medicine, University Hospital Jena, Jena 07747, Germany
| | - Birgit Waltenberger
- Institute of Pharmacy/Pharmacognosy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck 6020, Austria
| | - Tran Hung
- Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City 700000, Viet Nam
| | - Antonietta Rossi
- Department of Pharmacy, School of Medicine, University of Naples Federico II, Naples 80131, Italy
| | - Hermann Stuppner
- Institute of Pharmacy/Pharmacognosy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck 6020, Austria
| | - Oliver Werz
- Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, Jena 07743, Germany
| | - Andreas Koeberle
- Michael Popp Institute and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck 6020, Austria
- Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, Jena 07743, Germany
| |
Collapse
|
5
|
Wang Z, Kang W, Li O, Qi F, Wang J, You Y, He P, Suo Z, Zheng Y, Liu HM. Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. Acta Pharm Sin B 2021; 11:694-707. [PMID: 33777676 PMCID: PMC7982505 DOI: 10.1016/j.apsb.2020.11.005] [Citation(s) in RCA: 46] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2020] [Revised: 09/01/2020] [Accepted: 09/07/2020] [Indexed: 12/13/2022] Open
Abstract
Targeting immune checkpoints such as programmed cell death protein 1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved for treating melanoma, gastric cancer (GC) and bladder cancer with clinical benefit. Nevertheless, many patients failed to respond to anti-PD-1/PD-L1 treatment, so it is necessary to seek an alternative strategy for traditional PD-1/PD-L1 targeting immunotherapy. Here with the data from The Cancer Genome Atlas (TCGA) and our in-house tissue library, PD-L1 expression was found to be positively correlated with the expression of ubiquitin-specific processing protease 7 (USP7) in GC. Furthermore, USP7 directly interacted with PD-L1 in order to stabilize it, while abrogation of USP7 attenuated PD-L1/PD-1 interaction and sensitized cancer cells to T cell killing in vitro and in vivo. Besides, USP7 inhibitor suppressed GC cells proliferation by stabilizing P53 in vitro and in vivo. Collectively, our findings indicate that in addition to inhibiting cancer cells proliferation, USP7 inhibitor can also downregulate PD-L1 expression to enhance anti-tumor immune response simultaneously. Hence, these data posit USP7 inhibitor as an anti-proliferation agent as well as a novel therapeutic agent in PD-L1/PD-1 blockade strategy that can promote the immune response of the tumor.
Collapse
Key Words
- BCA, bicinchoninic acid
- CHX, cycloheximide
- CSN5, COP9 signalosome 5
- Cancer biology
- DUB, deubiquitinating enzymes
- EBNA1, Epstein–Barr nuclear antigen 1
- Epigenetics
- FDA, U.S. Food and Drug Administration
- FOXO4, forkhead box O4
- GC, gastric cancer
- GEPIA, Gene-Expression Profiling Interactive Analysis
- Gastric cancer
- H2O2, hydrogen peroxidase
- HAUSP, herpes virus-associated ubiquitin-specific protease
- HDN, well differentiated matched adjacent normal tissues
- HDT, well differentiated tumor tissues
- ICP0, infected cell protein 0
- IL-2, interleukin 2
- Immunosuppression
- Immunotherapy
- MDM2, murine double minute-2
- PBMC, peripheral blood mononuclear cells
- PBS, phosphate buffer saline
- PD-1, programmed cell death protein 1
- PD-L1
- PD-L1, programmed death ligand-1
- PDN, poor differentiated matched adjacent normal tissues
- PDT, poor differentiated tumor tissues
- PTMs, post-translational modifications
- RIPA, radioimmunoprecipitation
- TCGA, the Cancer Genome Atlas
- TCR, T cell receptor
- TILs, tumor-infiltrating T cells
- USP18, ubiquitin specific peptidase 18
- USP22, ubiquitin specific peptidase 22
- USP38, ubiquitin specific peptidase 38
- USP7
- USP7, ubiquitin-specific processing protease 7
- USP9X, ubiquitin specific peptidase 9 X-linked
- Ubiquitination
- WB, Western blotting
- irAEs, immune-related adverse effects
- qRT-PCR, quantitative real time polymerase chain reaction
Collapse
|
6
|
Ahmetaj-Shala B, Vaja R, Atanur SS, George PM, Kirkby NS, Mitchell JA. Cardiorenal Tissues Express SARS-CoV-2 Entry Genes and Basigin (BSG/CD147) Increases With Age in Endothelial Cells. JACC Basic Transl Sci 2020; 5:1111-1123. [PMID: 33073064 PMCID: PMC7546186 DOI: 10.1016/j.jacbts.2020.09.010] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Revised: 09/17/2020] [Accepted: 09/17/2020] [Indexed: 02/07/2023]
Abstract
Vascular and cardiovascular inflammation and thrombosis occur in patients with severe coronavirus disease-2019 (COVID-19). Advancing age is the most significant risk factor for severe COVID-19. Using transcriptomic databases, the authors found that: 1) cardiovascular tissues and endothelial cells express putative genes for severe acute respiratory syndrome coronavirus-2 infection, including angiotensin-converting enzyme 2 (ACE2) and basigin (BSG); 2) severe acute respiratory syndrome coronavirus-2 receptor pathways ACE2/transmembrane serine protease 2 and BSG/peptidylprolyl isomerase B(A) polarize to lung/epithelium and vessel/endothelium, respectively; 3) expression of host genes is relatively stable with age; and 4) notable exceptions are ACE2, which decreases with age in some tissues, and BSG, which increases with age in endothelial cells, suggesting that BSG expression in the vasculature may explain the heightened risk for severe disease with age.
Collapse
Key Words
- ACE2, angiotensin converting enzyme 2
- ADAM17, ADAM metallopeptidase domain 17
- BSG, basigin
- COVID-19
- COVID-19, coronavirus disease-2019
- CTSB, cathepsin B
- CTSL, cathepsin L
- GTEx, Genotype-Tissue Expression
- PBMC, peripheral blood mononuclear cells
- PPIA, peptidylprolyl isomerase A
- PPIB, peptidylprolyl isomerase B
- SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2
- TMPRSS2, transmembrane serine protease 2
- age
- cardiovascular
- endothelial cells
Collapse
Affiliation(s)
- Blerina Ahmetaj-Shala
- Cardiorespiratory Interface, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Ricky Vaja
- Cardiorespiratory Interface, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Santosh S. Atanur
- Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, United Kingdom
- Institute of Translational Medicine and Therapeutics, Data Science Group, National Institute for Health Research, Biomedical Research Centre, Imperial College London, London, United Kingdom
| | - Peter M. George
- Cardiorespiratory Interface, National Heart and Lung Institute, Imperial College London, London, United Kingdom
- Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom
| | - Nicholas S. Kirkby
- Cardiorespiratory Interface, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Jane A. Mitchell
- Cardiorespiratory Interface, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| |
Collapse
|
7
|
Lasseter HC, Provost AC, Chaby LE, Daskalakis NP, Haas M, Jeromin A. Cross-platform comparison of highly sensitive immunoassay technologies for cytokine markers: Platform performance in post-traumatic stress disorder and Parkinson's disease. Cytokine X 2020; 2:100027. [PMID: 33604555 PMCID: PMC7885879 DOI: 10.1016/j.cytox.2020.100027] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2019] [Revised: 03/25/2020] [Accepted: 04/10/2020] [Indexed: 12/14/2022] Open
Abstract
Cross-platform comparisons were conducted across five leading immunoassay platforms. Plasma and serum were obtained from healthy controls and clinical populations. Analytic parameters included sensitivity, precision, and performance correlation. Platform performance was highly variable, particularly for low-abundant cytokines. Findings highlight certain immunoassays should be prioritized in future research.
There is mounting evidence of systemic inflammation in post-traumatic stress disorder (PTSD) and Parkinson’s disease (PD), yet inconsistency and a lack of replicability in findings of putative biological markers have delayed progress in this space. Variability in performance between platforms may contribute to the lack of consensus in the biomarker literature, as has been seen for a number of psychiatric disorders, including PTSD. Thus, there is a need for high-performance, scalable, and validated platforms for the discovery and development of biomarkers of inflammation for use in drug development and as clinical diagnostics. To identify the best platform for use in future biomarker discovery efforts, we conducted a comprehensive cross-platform and cross-assay evaluation across five leading platform technologies. This initial assessment focused on four cytokines that have been implicated PTSD – interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ. To assess platform performance and understand likely measurements in individuals with brain disorders, serum and plasma samples were obtained from individuals with PTSD (n = 13) or Parkinson’s Disease (n = 14) as well as healthy controls (n = 5). We compared platform performance across a number of common analytic parameters, including assay precision, sensitivity, frequency of endogenous analyte detection (FEAD), correlation between platforms, and parallelism in measurement of cytokines using a serial dilution series. The single molecule array (Simoa™) ultra-sensitive platform (Quanterix), MESO V-Plex (Mesoscale Discovery), and Luminex xMAP® (Myriad) were conducted by their respective vendors, while Luminex® and Quantikine® high-sensitivity ELISA assays were evaluated by R&D System’s Biomarker Testing Services. The assay with the highest sensitivity in detecting endogenous analytes across all analytes and clinical populations (i.e. the highest FEAD), was the Simoa™ platform. In contrast, more variable performance was observed for MESO V-plex, R&D Luminex® and Quantikine®, while Myriad’s Luminex xMAP® exhibited low FEAD across all analytes and samples. Simoa™ also demonstrated high precision in detecting endogenous cytokines, as reflected in < 20 percent coefficient of variance (%CV) across replicate runs for samples from the healthy controls, PTSD patients, and PD patients. In contrast, MESO V-Plex, R&D Luminex® and Quantikine® had variable performance in terms of precision across cytokines. Myriad Luminex xMAP® could not be included in precision estimates because the vendor did not run samples in duplicate. For cross-platform performance comparisons, the highest cross-platform correlations were observed for IL-6 such that all platforms – except for Myriad’s Luminex xMAP® – had strong correlations with one another in measurements of IL-6 (r range = 0.59 – 0.86). For the other cytokines, there was low to no correlation across platforms, such that reported measurements of IL-1β, TNF-α, and IFN-γ varied across assays. Taken together, these findings provide novel evidence that the choice of immunoassay could greatly impact reported cytokine findings. The current study provides crucial information on the variability in performance between platforms and across immunoassays that may help inform the selection of assay in future research studies. Further, the results emphasize the need for performing comparative evaluations of immunoassays as new technologies emerge over time, particularly given the lack of reference standards for the quantitative assessments of cytokines.
Collapse
Key Words
- BLQ, below limit of quantification
- Biomarker
- CV, coefficient of variance
- Cytokine
- FEAD, frequency of endogenous analyte detection
- IFN-γ, interferon-γ
- IL-1β, interleukin-1β
- IL-6, interleukin-6
- IUGB, Indiana University Genetics Biobank
- Immunoassay
- LLOD, lower limit of detection
- LLOQ, lower limit of quantification
- MSD, Mesoscale Discovery
- PBMC, peripheral blood mononuclear cells
- PD, Parkinson’s disease
- PMA, phorbol myristate acetate
- PTSD, post-traumatic stress disorder
- Parkinson’s disease
- Post-traumatic stress disorder
- TNF-α, tumor necrosis factor-α
- ULOD, upper limit of detection
- ULOQ, upper limit of quantification
- Ultrasensitive technologies
Collapse
Affiliation(s)
- Heather C Lasseter
- Cohen Veterans Bioscience Inc., 535 8th Avenue, 12th Floor, New York, NY 10018, United States
| | - Allison C Provost
- Cohen Veterans Bioscience Inc., 535 8th Avenue, 12th Floor, New York, NY 10018, United States
| | - Lauren E Chaby
- Cohen Veterans Bioscience Inc., 535 8th Avenue, 12th Floor, New York, NY 10018, United States
| | - Nikolaos P Daskalakis
- Cohen Veterans Bioscience Inc., 535 8th Avenue, 12th Floor, New York, NY 10018, United States
| | - Magali Haas
- Cohen Veterans Bioscience Inc., 535 8th Avenue, 12th Floor, New York, NY 10018, United States
| | - Andreas Jeromin
- Cohen Veterans Bioscience Inc., 535 8th Avenue, 12th Floor, New York, NY 10018, United States
| |
Collapse
|
8
|
Teyssier L, Sorci G, Chluba J, Aimé S, Wendehenne D, Lamotte O, Connat JL. Some Plant Defense Stimulators can induce IL-1β production in human immune cells in vitro. Toxicol Rep 2020; 7:413-20. [PMID: 32140425 DOI: 10.1016/j.toxrep.2020.02.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2019] [Accepted: 02/17/2020] [Indexed: 11/23/2022] Open
Abstract
Among Plant Protection Products (PPP), a new emerging category of pesticides act by stimulating plant defense in order to improve plant resistance against microbial pathogens. Given that these compounds, the so-called Plant Defense Stimulators (PDS) act on innate immunity, we tested, using an in vitro approach on human mononuclear leucocytes (PBMC), the potential toxicity (XTT assay) and inflammatory effects (production of IL-1β) of 4 PPP belonging to different chemical families. We found that two products (LBG-01F34® and Regalis®) did not induce any cytotoxicity or IL-1 β production. The product BION-50 WG®, that contains Acibenzolar-S-methyl (ASM) and silica particles did not present any cytotoxicity but induced a significant increase in the production of the inflammatory cytokine IL-1 β. Finally, Vacciplant® that contains laminarin, was highly cytotoxic and pro-inflammatory. It induced a strong production of IL-1 β when used at a concentration in the culture medium, as low as 0.02 mg/mL. We also tested the potential toxic effect of these 4 PPP on 4 days old zebra fish larvae. After 24 h of exposure, our results indicate that Vacciplant® induced zebra fish larvae mortality at concentration of 20 μg/mL. LBG did not induced significant mortality at concentrations up to 1 mg/mL whereas Regalis was lethal for 0,3 mg/mL concentrations and BION-50 WG began to induce mortality at 2,5 mg/mL. Our results indicate possible effects of PDS on IL-1β production in human cells and fish survival, calling for more studies on the potential noxious side effects of these compounds.
Collapse
|
9
|
Segal-Salto M, Barashi N, Katav A, Edelshtein V, Aharon A, Hashmueli S, George J, Maor Y, Pinzani M, Haberman D, Hall A, Friedman S, Mor A. A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. JHEP Rep 2020; 2:100064. [PMID: 32039405 PMCID: PMC7005554 DOI: 10.1016/j.jhepr.2019.100064] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2019] [Revised: 12/10/2019] [Accepted: 12/15/2019] [Indexed: 12/19/2022] Open
Abstract
Background & Aims C-C motif chemokine ligand 24 (CCL24) is a chemokine that regulates inflammatory and fibrotic activities through its receptor, C-C motif chemokine receptor (CCR3). The aim of the study was to evaluate the involvement of the CCL24-CCR3 axis in liver fibrosis and inflammation and to assess the potential of its blockade, by a monoclonal anti-CCL24 antibody, as a therapeutic strategy for non-alcoholic steatohepatitis (NASH) and liver fibrosis. Methods Expression of CCL24 and CCR3 was evaluated in liver biopsies and blood samples. CCL24 involvement in NAFLD/NASH pathogenesis was assessed in Ccl24 knockout mouse using the methionine-choline deficient (MCD) diet experimental model. Antifibrotic and anti-inflammatory effects of CM-101 were tested in the MCD and STAM mouse models and in the thioacetamide (TAA) model in rats. Liver enzymes, liver morphology, histology and collagen deposition, as well as fibrosis- and inflammation-related protein expression were assessed. Activation of hepatic stellate cells (HSCs) was evaluated in the human LX2 cell line. Results Patients with NASH and advanced NAFLD exhibited significant expression of both CCL24 and CCR3 in liver and blood samples. In the experimental MCD-diet model, Ccl24 knockout mice showed an attenuated liver damage response compared to wild-type mice, exhibiting reduced histological NAFLD activity scores and fibrosis, as well as lower levels of liver enzymes. Blocking CCL24 using CM-101 robustly reduced liver damage in 3 experimental animal models (MCD, STAM and TAA), as demonstrated by attenuation of liver fibrosis and NAFLD activity score. Furthermore, blocking CCL24 by CM-101 significantly inhibited CCL24-induced HSC motility, α-SMA expression and pro-collagen I secretion. Conclusion Our results reveal that blocking CCL24 significantly attenuates liver fibrosis and inflammation and may have a potential therapeutic effect in patients with NASH and/or liver fibrosis. Lay summary CCL24 is a chemokine that regulates inflammation and fibrosis. It was found to be significantly expressed in patients with non-alcoholic steatohepatitis, in whom it regulates profibrotic processes in the liver. Herein, we show that blockade of CCL24 using a monoclonal antibody robustly attenuated liver fibrosis and inflammation in animal models, thus suggesting a potential therapeutic role for an anti-CCL24 agent. CCL24 is a chemokine that regulates inflammatory and fibrotic activities through its receptor, CCR3. Significant expression of CCL24 and CCR3 were found in liver biopsies and blood samples from patients with NAFLD/NASH. CM-101, a monoclonal antibody that selectively targets CCL24, significantly attenuates fibrotic and inflammatory processes. Blocking CCL24 may have a potential therapeutic effect in NASH and liver fibrosis.
Collapse
Key Words
- ALT, alanine aminotransferase
- AST, aspartate aminotransferase
- Antibody
- C-C motif chemokine ligand 24
- CCL24
- CCL24, C-C motif chemokine ligand 24
- CCR3, C-C motif chemokine receptor 3
- CM-101
- Fibrosis
- HSCs, hepatic stellate cells
- IL-6, interleukin-6
- MCD, methionine-choline deficient
- MFI, median fluorescence intensity
- MMP, matrix metallopeptidase
- NAFLD, non-alcoholic fatty liver disease
- NAS, NAFLD activity score
- NASH, non-alcoholic steatohepatitis
- Non-alcoholic fatty liver disease
- Non-alcoholic steatohepatitis
- PBMC, peripheral blood mononuclear cells
- TAA, thioacetamide
- WT, wild-type
- α-SMA, α-smooth muscle actin
Collapse
Affiliation(s)
| | | | | | | | | | | | - Jacob George
- Heart Center, Kaplan Medical Center, Rehovot, Affiliated to the Hebrew University, Jerusalem, Israel
| | - Yaakov Maor
- Institute of Gastroenterology and Hepatology, Kaplan Medical Center, Rehovot, Israel
| | - Massimo Pinzani
- UCL Institute for Liver and Digestive Health, University College of London, London, UK.,Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, London, UK
| | - Dan Haberman
- Heart Center, Kaplan Medical Center, Rehovot, Affiliated to the Hebrew University, Jerusalem, Israel
| | - Andrew Hall
- UCL Institute for Liver and Digestive Health, University College of London, London, UK.,Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, London, UK
| | - Scott Friedman
- Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, NY, USA
| | | |
Collapse
|
10
|
Øyri LKL, Narverud I, Bogsrud MP, Hansson P, Leder L, Byfuglien MG, Veierød MB, Thoresen M, Ulven SM, Holven KB. Postprandial changes in gene expression of cholesterol influx and efflux mediators after intake of SFA compared with n-6 PUFA in subjects with and without familial hypercholesterolaemia: secondary outcomes of a randomised controlled trial. J Nutr Sci 2019; 8:e27. [PMID: 31448116 DOI: 10.1017/jns.2019.25] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2019] [Revised: 07/04/2019] [Accepted: 07/09/2019] [Indexed: 12/24/2022] Open
Abstract
The long-term cholesterol-lowering effect of replacing intake of SFA with PUFA is well established, but has not been fully explained mechanistically. We examined the postprandial response of meals with different fat quality on expression of lipid genes in peripheral blood mononuclear cells (PBMC) in subjects with and without familial hypercholesterolaemia (FH). Thirteen subjects with FH (who had discontinued lipid-lowering treatment ≥4 weeks prior to both test days) and fourteen normolipidaemic controls were included in a randomised controlled double-blind crossover study with two meals, each with 60 g of fat either mainly SFA (about 40% energy) or n-6 PUFA (about 40% energy). PBMC were isolated in fasting, and 4 and 6 h postprandial blood samples. Expression of thirty-three lipid genes was analysed by reverse transcription quantitative PCR. A linear mixed model was used to assess postprandial effects between meals and groups. There was a significant interaction between meal and group for MSR1 (P = 0·03), where intake of SFA compared with n-6 PUFA induced a larger reduction in gene expression in controls only (P = 0·01). Intake of SFA compared with n-6 PUFA induced larger reductions in gene expression levels of LDLR and FADS1/2, smaller increases of INSIG1 and FASN, and larger increases of ABCA1 and ABCG1 (P = 0·01 for all, no group interaction). Intake of SFA compared with n-6 PUFA induced changes in gene expression of cholesterol influx and efflux mediators in PBMC including lower LDLR and higher ABCA1/G1, potentially explaining the long-term cholesterol-raising effect of a high SFA intake.
Collapse
|
11
|
Lacey M, Baribault C, Ehrlich KC, Ehrlich M. Data showing atherosclerosis-associated differentially methylated regions are often at enhancers. Data Brief 2019; 23:103812. [PMID: 31372457 PMCID: PMC6660590 DOI: 10.1016/j.dib.2019.103812] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Revised: 02/22/2019] [Accepted: 02/26/2019] [Indexed: 12/22/2022] Open
Abstract
Atherosclerosis involves phenotypic modulation and transdifferentiation of vascular smooth muscle cells (SMCs). Data are given in tabular or figure format that illustrate genome-wide DNA methylation alterations in atherosclerotic vs. control aorta (athero DMRs). Data based upon publicly available chromatin state profiles are also shown for normal aorta, monocyte, and skeletal muscle tissue-specific DMRs and for aorta-specific chromatin features (enhancer chromatin, promoter chromatin, repressed chromatin, actively transcribed chromatin). Athero hypomethylated and hypermethylated DMRs as well as epigenetic and transcription profiles are described for the following genes: ACTA2, MYH10, MYH11 (SMC-associated genes); SMAD3 (a signaling gene for SMCs and other cell types); CD79B and SH3BP2 (leukocyte-associated genes); and TBX20 and genes in the HOXA, HOXB, HOXC, and HOXD clusters (T-box and homeobox developmental genes). The data reveal strong correlations between athero hypermethylated DMRs and regions of enhancer chromatin in aorta, which are discussed in the linked research article “Atherosclerosis-associated differentially methylated regions can reflect the disease phenotype and are often at enhancers” (M. Lacey et al., 2019).
Collapse
Key Words
- Atherosclerosis
- DMR, differentially methylated region
- DNA methylation
- Differentially methylated regions (DMRs)
- Enhancers
- GO, gene ontology
- Monocytes
- PBMC, peripheral blood mononuclear cells
- PMD, percent methylation difference
- SkM, skeletal muscle
- Smooth muscle
- athero hypermeth DMR, atherosclerosis-associated hypermethylated DMR
- athero hypometh DMR, atherosclerosis-associated hypomethylated DMR
- ctl, control
- enh, enhancer chromatin
- mod, moderate
- prom, promoter chromatin
- repr, repressed
- txn chromatin, chromatin with the histone marks of actively transcribed chromatin
Collapse
Affiliation(s)
- Michelle Lacey
- Tulane Cancer Center, Tulane University Health Sciences Center, LA 70112, USA.,Department of Mathematics, Tulane University, New Orleans, LA 70118, USA
| | - Carl Baribault
- Tulane Cancer Center, Tulane University Health Sciences Center, LA 70112, USA
| | - Kenneth C Ehrlich
- Center for Bioinformatics and Genomics, Tulane University Health Sciences Center, USA
| | - Melanie Ehrlich
- Tulane Cancer Center, Tulane University Health Sciences Center, LA 70112, USA.,Center for Bioinformatics and Genomics, Tulane University Health Sciences Center, USA.,Hayward Genetics Center, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
| |
Collapse
|
12
|
Islam MA, Hooiveld GJEJ, van den Berg JHJ, van der Velpen V, Murk AJ, Rietjens IMCM, van Leeuwen FXR. Soy supplementation: Impact on gene expression in different tissues of ovariectomized rats and evaluation of the rat model to predict (post)menopausal health effect. Toxicol Rep 2018; 5:1087-1097. [PMID: 30425930 PMCID: PMC6222031 DOI: 10.1016/j.toxrep.2018.10.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2018] [Revised: 09/29/2018] [Accepted: 10/18/2018] [Indexed: 11/06/2022] Open
Abstract
The usefulness of PBMC gene expressions as a surrogate tissue for risk assessment is questionable. SIF in a dose of 2 mg/kg b.w/day is not able to influence ERGs in target tissues such as breast and uterus. Plasma concentrations of SIF after 8 weeks oral exposure similar as the recommended dose for humans do not proliferate cells in in vitro cellular models. The ovariectomized rat is probably not a good model to predict human risk or benefit assessment of SIF in human.
This toxicogenomic study was conducted to predict (post)menopausal human health effects of commercial soy supplementation using ovariectomized rats as a model. Different target tissues (i.e. breast, uterus and sternum) and non-target tissues (i.e. peripheral blood mononuclear cells (PBMC), adipose and liver) of ovariectomized F344 rats exposed to a commercially available soy supplement for eight weeks, were investigated. Changes in gene expression in these tissues were analysed using whole-genome microarray analysis. No correlation in changes in gene expression were observed among different tissues, indicating tissue specific effects of soy isoflavone supplementation. Out of 87 well-established estrogen responsive genes (ERGs), only 19 were found to be significantly regulated (p < 0.05) in different tissues, particularly in liver, adipose and uterus tissues. Surprisingly, no ERGs were significantly regulated in estrogen sensitive breast and sternum tissues. The changes in gene expression in PBMC and adipose tissue in rats were compared with those in (post)menopausal female volunteers who received the same supplement in a similar oral dose and exposure duration in human intervention studies. No correlation in changes in gene expression between rats and humans was observed. Although receiving a similar dose, in humans the plasma levels expressed as total free aglycones were several folds higher than in the rat. Therefore, the overall results in young ovariectomized female F344 rats indicated that using rat transcriptomic data does not provide a suitable model for human risk or benefit analysis of soy isoflavone supplementation.
Collapse
Affiliation(s)
- Mohammed A Islam
- Division of Toxicology, Wageningen University, Stippeneng 4, 6708 WE Wageningen, the Netherlands.,Department of Agricultural Chemistry, Sher-e-Bangla Agricultural University, Dhaka, Bangladesh
| | - Guido J E J Hooiveld
- Division of Human Nutrition, Wageningen University, Bomenweg 2, 6703 HE Wageningen, the Netherlands
| | | | - Vera van der Velpen
- Division of Human Nutrition, Wageningen University, Bomenweg 2, 6703 HE Wageningen, the Netherlands.,Metabolomics Service and Research Unit, Faculty of Biology and Medicine, University of Lausanne, Switzerland
| | - Albertinka J Murk
- Division of Toxicology, Wageningen University, Stippeneng 4, 6708 WE Wageningen, the Netherlands.,Sub-department of Environmental Technology, Wageningen University, the Netherlands
| | - Ivonne M C M Rietjens
- Division of Toxicology, Wageningen University, Stippeneng 4, 6708 WE Wageningen, the Netherlands
| | - F X Rolaf van Leeuwen
- Division of Toxicology, Wageningen University, Stippeneng 4, 6708 WE Wageningen, the Netherlands
| |
Collapse
|
13
|
Wiik A, Andersson DP, Brismar TB, Chanpen S, Dhejne C, Ekström TJ, Flanagan JN, Holmberg M, Kere J, Lilja M, Lindholm ME, Lundberg TR, Maret E, Melin M, Olsson SM, Rullman E, Wåhlén K, Arver S, Gustafsson T. Metabolic and functional changes in transgender individuals following cross-sex hormone treatment: Design and methods of the GEnder Dysphoria Treatment in Sweden (GETS) study. Contemp Clin Trials Commun 2018; 10:148-153. [PMID: 30023449 PMCID: PMC6046513 DOI: 10.1016/j.conctc.2018.04.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2017] [Revised: 04/05/2018] [Accepted: 04/11/2018] [Indexed: 11/16/2022] Open
Abstract
Background Although the divergent male and female differentiation depends on key genes, many biological differences seen in men and women are driven by relative differences in estrogen and testosterone levels. Gender dysphoria denotes the distress that gender incongruence with the assigned sex at birth may cause. Gender-affirming treatment includes medical intervention such as inhibition of endogenous sex hormones and subsequent replacement with cross-sex hormones. The aim of this study is to investigate consequences of an altered sex hormone profile on different tissues and metabolic risk factors. By studying subjects undergoing gender-affirming medical intervention with sex hormones, we have the unique opportunity to distinguish between genetic and hormonal effects. Methods The study is a single center observational cohort study conducted in Stockholm, Sweden. The subjects are examined at four time points; before initiation of treatment, after endogenous sex hormone inhibition, and three and eleven months following sex hormone treatment. Examinations include blood samples, skeletal muscle-, adipose- and skin tissue biopsies, arteriography, echocardiography, carotid Doppler examination, whole body MRI, CT of muscle and measurements of muscle strength. Results The primary outcome measure is transcriptomic and epigenomic changes in skeletal muscle. Secondary outcome measures include transcriptomic and epigenomic changes associated with metabolism in adipose and skin, muscle strength, fat cell size and ability to release fatty acids from adipose tissue, cardiovascular function, and body composition. Conclusions This study will provide novel information on the role of sex hormone treatment in skeletal muscle, adipose and skin, and its relation to cardiovascular and metabolic disease.
Collapse
Affiliation(s)
- Anna Wiik
- Department of Laboratory Medicine, Karolinska Institutet, Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden
| | - Daniel P. Andersson
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
- Corresponding author. Department of Medicine (H7) C2:94, Karolinska Institutet, 14186 Stockholm, Sweden.
| | - Torkel B. Brismar
- Division of Radiology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Setareh Chanpen
- ANOVA, Andrology, Sexual Medicine and Transgender Medicine, Karolinska University Hospital, Stockholm, Sweden
| | - Cecilia Dhejne
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
- ANOVA, Andrology, Sexual Medicine and Transgender Medicine, Karolinska University Hospital, Stockholm, Sweden
| | - Tomas J. Ekström
- Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
| | - John N. Flanagan
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
| | - Mats Holmberg
- ANOVA, Andrology, Sexual Medicine and Transgender Medicine, Karolinska University Hospital, Stockholm, Sweden
| | - Juha Kere
- Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden
| | - Mats Lilja
- Department of Laboratory Medicine, Karolinska Institutet, Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden
| | - Malene E. Lindholm
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
| | - Tommy R. Lundberg
- Department of Laboratory Medicine, Karolinska Institutet, Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden
| | - Eva Maret
- Department of Laboratory Medicine, Karolinska Institutet, Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden
| | - Michael Melin
- Heart and Vascular Theme, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
| | - Sofie M. Olsson
- Department of Laboratory Medicine, Karolinska Institutet, Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden
| | - Eric Rullman
- Department of Laboratory Medicine, Karolinska Institutet, Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden
- Heart and Vascular Theme, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
| | - Kerstin Wåhlén
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
| | - Stefan Arver
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
| | - Thomas Gustafsson
- Department of Laboratory Medicine, Karolinska Institutet, Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
14
|
Yao Q, Fischer KP, Tyrrell DL, Gutfreund KS. The Pekin duck programmed death ligand-2: cDNA cloning, genomic structure, molecular characterization and expression analysis. Biochem Biophys Rep 2018; 13:116-122. [PMID: 29556566 PMCID: PMC5857182 DOI: 10.1016/j.bbrep.2018.01.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Accepted: 01/22/2018] [Indexed: 11/27/2022] Open
Abstract
Programmed death-1 (PD-1), upon engagement by its ligands, programmed death ligand-1 (PD-L1) and programmed death ligand-2 (PD-L2), provides signals that attenuate adaptive immune responses. Here we describe the identification of the Pekin duck PD-L2 (duPD-L2) and its gene structure. The duPD-L2 cDNA encodes a 321 amino acid protein that has an amino acid identity of 76% and 35% with chicken and human PD-L2, respectively. Mapping of the duPD-L2 cDNA with duck genomic sequences revealed an exonic structure similar to that of the human Pdcd1lg2 gene. Homology modelling of the duPD-L2 protein was compatible with the murine PD-L2 ectodomain structure. Residues known to be important for PD-1 receptor binding of murine PD-L2 were mostly conserved in duPD-L2 within sheets A and G and partially conserved within sheets C and F. DuPD-L2 mRNA was constitutively expressed in all tissues examined with highest expression levels in lung, spleen, cloaca, bursa, cecal tonsil, duodenum and very low levels of expression in muscle, kidney and brain. Lipopolysaccharide treatment of adherent duck PBMC upregulated duPD-L2 mRNA expression. Our work shows evolutionary conservation of the PD-L2 ectodomain structure and residues important for PD-1 binding in vertebrates including fish. The information provided will be useful for further investigation of the role of duPD-L2 in the regulation of duck adaptive immunity and exploration of PD-1-targeted immunotherapies in the duck hepatitis B infection model.
Collapse
Affiliation(s)
- Qingxia Yao
- Depts. of Medicine, University of Alberta, Edmonton, AB, Canada.,Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB, Canada
| | - Karl P Fischer
- Medical Microbiology & Immunology, University of Alberta, Edmonton, AB, Canada.,Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB, Canada
| | - D Lorne Tyrrell
- Depts. of Medicine, University of Alberta, Edmonton, AB, Canada.,Medical Microbiology & Immunology, University of Alberta, Edmonton, AB, Canada.,Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB, Canada
| | - Klaus S Gutfreund
- Depts. of Medicine, University of Alberta, Edmonton, AB, Canada.,Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB, Canada
| |
Collapse
|
15
|
Rundblad A, Holven KB, Bruheim I, Myhrstad MC, Ulven SM. Effects of fish and krill oil on gene expression in peripheral blood mononuclear cells and circulating markers of inflammation: a randomised controlled trial. J Nutr Sci 2018; 7:e10. [PMID: 29599972 DOI: 10.1017/jns.2018.2] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2016] [Accepted: 01/23/2018] [Indexed: 12/14/2022] Open
Abstract
Marine n-3 (omega-3) fatty acids alter gene expression by regulating the activity of transcription factors. Krill oil is a source of marine n-3 fatty acids that has been shown to modulate gene expression in animal studies; however, the effect in humans is not known. Hence, we aimed to compare the effect of intake of krill oil, lean and fatty fish with a similar content of n-3 fatty acids, and high-oleic sunflower oil (HOSO) with added astaxanthin on the expression of genes involved in glucose and lipid metabolism and inflammation in peripheral blood mononuclear cells (PBMC) as well as circulating inflammatory markers. In an 8-week trial, healthy men and women aged 18–70 years with fasting TAG of 1·3–4·0 mmol/l were randomised to receive krill oil capsules (n 12), HOSO capsules (n 12) or lean and fatty fish (n 12). The weekly intakes of marine n-3 fatty acids from the interventions were 4654, 0 and 4103 mg, respectively. The mRNA expression of four genes, PPAR γ coactivator 1A (PPARGC1A), steaoryl-CoA desaturase (SCD), ATP binding cassette A1 (ABCA1) and cluster of differentiation 40 (CD40), were differently altered by the interventions. Furthermore, within-group analyses revealed that krill oil down-regulated the mRNA expression of thirteen genes, including genes involved in glucose and cholesterol metabolism and β-oxidation. Fish altered the mRNA expression of four genes and HOSO down-regulated sixteen genes, including several inflammation-related genes. There were no differences between the groups in circulating inflammatory markers after the intervention. In conclusion, the intake of krill oil and HOSO with added astaxanthin alter the PBMC mRNA expression of more genes than the intake of fish.
Collapse
Key Words
- ABCA1, ATP binding cassette A1
- ACADVL, acyl-CoA dehydrogenase, very long chain
- CD40, cluster of differentiation 40
- CPT, carnitine palmitoyltransferase
- Ct, cycle threshold
- Fish
- Gene expression
- Glucose
- HMGCR, 3-hyroxy-3-methylglutaryl-coenzyme A reductase
- HMGCS, 3-hydroxy-3-methylglutaryl-coA synthase
- HOSO, high-oleic sunflower oil
- ICAM-1, intracellular adhesion molecule-1
- Krill oil
- Marine n-3 fatty acids
- PBMC, peripheral blood mononuclear cells
- PPARGC1A, PPAR γ coactivator 1A
- Peripheral blood mononuclear cells
- SCD, steaoryl-CoA desaturase
- SLC25A12, solute carrier family 25 member 12
- SREBP-1c, sterol-regulating element binding protein 1c
- UCP2, uncoupling protein 2
- VCAM-1, vascular cell adhesion molecule-1
Collapse
|
16
|
Turiján-Espinoza E, Salazar-González RA, Uresti-Rivera EE, Hernández-Hernández GE, Ortega-Juárez M, Milán R, Portales-Pérez D. A pilot study of the modulation of sirtuins on arylamine N-acetyltransferase 1 and 2 enzymatic activity. Acta Pharm Sin B 2018; 8:188-199. [PMID: 29719779 PMCID: PMC5926248 DOI: 10.1016/j.apsb.2017.11.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Revised: 11/15/2017] [Accepted: 11/17/2017] [Indexed: 11/25/2022] Open
Abstract
Arylamine N-acetyltransferase (NAT; E.C. 2.3.1.5) enzymes are responsible for the biotransformation of several arylamine and hydrazine drugs by acetylation. In this process, the acetyl group transferred to the acceptor substrate produces NAT deacetylation and, in consequence, it is susceptible of degradation. Sirtuins are protein deacetylases, dependent on nicotine adenine dinucleotide, which perform post-translational modifications on cytosolic proteins. To explore possible sirtuin participation in the enzymatic activity of arylamine NATs, the expression levels of NAT1, NAT2, SIRT1 and SIRT6 in peripheral blood mononuclear cells (PBMC) from healthy subjects were examined by flow cytometry and Western blot. The in situ activity of the sirtuins on NAT enzymatic activity was analyzed by HPLC, in the presence or absence of an agonist (resveratrol) and inhibitor (nicotinamide) of sirtuins. We detected a higher percentage of positive cells for NAT2 in comparison with NAT1, and higher numbers of SIRT1+ cells compared to SIRT6 in lymphocytes. In situ NAT2 activity in the presence of NAM inhibitors was higher than in the presence of its substrate, but not in the presence of resveratrol. In contrast, the activity of NAT1 was not affected by sirtuins. These results showed that NAT2 activity might be modified by sirtuins.
Collapse
Key Words
- APC, allophycocyanin
- Ac-INH, acetyl-Isoniazid
- Ac-PABA, acetyl-p-aminobenzoic acid
- Arylamine N-acetyltransferase
- CHO, Chinese hamster ovary cells
- DMEM, Dulbecco's modified Eagle's medium
- E2F1, E2F transctriptios factor 1
- ER81, ETS-related protein 81
- FITC, fluorescein IsoTioCyanate
- FOXO1, forkhead box protein O1
- HPLC, high performance liquid chromatography
- HeLa, adenocarcinoma epithelial cells
- INH, isoniazid
- NAD, nicotinamide adenine dinucleotide
- NAM, nicotinamide
- NAT
- NAT, arylamine N-acetyltranferase
- Nicotinamide
- PABA, p-aminobenzoic acid
- PAS, p-aminosalicilic acid
- PBMC, peripheral blood mononuclear cells
- PBS, phosphate-buffered saline
- PGAM1, phosphoglycerate mutase 1
- PGC-1α, peroxisome proliferator-activated receptor-gamma coactivator 1α
- Peripheral blood mononuclear cells
- RSV, resveratrol
- RUNX3, runt-related transcription factor 3
- Resveratrol
- SIRT, sirtuin
- SMZ, sulfamethazine
- SREBP1a, sterol regulatory element-binding protein 1a
- SREBP2, sterol regulatory element-binding protein 2
- Sirtuins
Collapse
Affiliation(s)
- Eneida Turiján-Espinoza
- Laboratory of Immunology and Cellular and Molecular Biology, Faculty of Chemical Science, UASLP, San Luis Potosi, Mexico
- Laboratory of Biopharmacy and Pharmacokinetics, Faculty of Chemical Science, UASLP, San Luis Potosi, Mexico
- Corresponding authors. Tel.: (52-44) 82624-40, ext. 6465 and 6594.
| | - Rául Alejandro Salazar-González
- Laboratory of Immunology and Cellular and Molecular Biology, Faculty of Chemical Science, UASLP, San Luis Potosi, Mexico
- Laboratory of Biopharmacy and Pharmacokinetics, Faculty of Chemical Science, UASLP, San Luis Potosi, Mexico
| | - Edith Elena Uresti-Rivera
- Laboratory of Immunology and Cellular and Molecular Biology, Faculty of Chemical Science, UASLP, San Luis Potosi, Mexico
| | | | - Montserrat Ortega-Juárez
- Laboratory of Immunology and Cellular and Molecular Biology, Faculty of Chemical Science, UASLP, San Luis Potosi, Mexico
| | - Rosa Milán
- Laboratory of Biopharmacy and Pharmacokinetics, Faculty of Chemical Science, UASLP, San Luis Potosi, Mexico
| | - Diana Portales-Pérez
- Laboratory of Immunology and Cellular and Molecular Biology, Faculty of Chemical Science, UASLP, San Luis Potosi, Mexico
- Corresponding authors. Tel.: (52-44) 82624-40, ext. 6465 and 6594.
| |
Collapse
|
17
|
Booth JS, Patil SA, Ghazi L, Barnes R, Fraser CM, Fasano A, Greenwald BD, Sztein MB. Systemic and Terminal Ileum Mucosal Immunity Elicited by Oral Immunization With the Ty21a Typhoid Vaccine in Humans. Cell Mol Gastroenterol Hepatol 2017; 4:419-437. [PMID: 29022005 PMCID: PMC5626924 DOI: 10.1016/j.jcmgh.2017.08.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Accepted: 08/04/2017] [Indexed: 12/10/2022]
Abstract
BACKGROUND & AIMS Systemic cellular immunity elicited by the Ty21a oral typhoid vaccine has been extensively characterized. However, very limited data are available in humans regarding mucosal immunity at the site of infection (terminal ileum [TI]). Here we investigated the host immunity elicited by Ty21a immunization on terminal ileum-lamina propria mononuclear cells (LPMC) and peripheral blood in volunteers undergoing routine colonoscopy. METHODS We characterized LPMC-T memory (TM) subsets and assessed Salmonella enterica serovar Typhi (S Typhi)-specific responses by multichromatic flow cytometry. RESULTS No differences were observed in cell yields and phenotypes in LPMC CD8+-TM subsets following Ty21a immunization. However, Ty21a immunization elicited LPMC CD8+ T cells exhibiting significant S Typhi-specific responses (interferon-γ, tumor necrosis factor-α, interleukin-17A, and/or CD107a) in all major TM subsets (T-effector/memory [TEM], T-central/memory, and TEM-CD45RA+), although each TM subset exhibited unique characteristics. We also investigated whether Ty21a immunization elicited S Typhi-specific multifunctional effectors in LPMC CD8+ TEM. We observed that LPMC CD8+ TEM responses were mostly multifunctional, except for those cells exhibiting the characteristics associated with cytotoxic responses. Finally, we compared mucosal with systemic responses and made the important observation that LPMC CD8+S Typhi-specific responses were unique and distinct from their systemic counterparts. CONCLUSIONS This study provides the first demonstration of S Typhi-specific responses in the human terminal ileum mucosa and provides novel insights into the generation of mucosal immune responses following oral Ty21a immunization.
Collapse
Key Words
- CD8+-T Memory Cells
- CMI, cell-mediated immune responses
- EBV-B, Epstein-Barr virus–transformed lymphoblastoid B cells
- IFN, interferon
- IL, interleukin
- LPMC, lamina propria mononuclear cells
- Lamina Propria Mononuclear Cells
- MF, multifunctional
- MIP, macrophage inflammatory protein
- Multifunctional T Cells
- PBMC, peripheral blood mononuclear cells
- S, S Typhi–specific single producing cells
- TCM, T-central/memory (CD62L+CD45RA-)
- TEM, T-effector/memory (CD62L-CD45RA-)
- TEMRA, TEM-CD45RA+ (CD62L-CD45RA+)
- TI, terminal ileum
- TM, CD8+ T memory
- TNF, tumor necrosis factor
- Typhoid
- Vaccines
- wt, wild-type
Collapse
Affiliation(s)
- Jayaum S. Booth
- Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland
- Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland
| | - Seema A. Patil
- Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland
- Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland
| | - Leyla Ghazi
- Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland
- Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland
| | - Robin Barnes
- Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland
| | - Claire M. Fraser
- Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland
- Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland
| | - Alessio Fasano
- Mucosal Immunology and Biology Research Center, Massachusetts General Hospital for Children, Boston, Massachusetts
| | - Bruce D. Greenwald
- Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland
- Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland
| | - Marcelo B. Sztein
- Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland
- Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland
- Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland
- Correspondence Address correspondence to: Dr. Marcelo B. Sztein, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201. fax: (410) 706 6205.Center for Vaccine DevelopmentUniversity of Maryland School of MedicineBaltimoreMaryland 21201
| |
Collapse
|
18
|
Wani SA, Sahu AR, Saxena S, Hussain S, Pandey A, Kanchan S, Sahoo AP, Mishra B, Tiwari AK, Mishra BP, Gandham RK, Singh RK. Systems biology approach: Panacea for unravelling host-virus interactions and dynamics of vaccine induced immune response. Gene Rep 2016; 5:23-29. [PMID: 32289096 PMCID: PMC7104209 DOI: 10.1016/j.genrep.2016.08.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Revised: 06/24/2016] [Accepted: 08/01/2016] [Indexed: 12/18/2022]
Abstract
Systems biology is an interdisciplinary research field in life sciences, which involves a comprehensive and quantitative analysis of the interactions between all of the components of biological systems over time. For the past 50 years the discipline of virology has overly focused on the pathogen itself. However, we now know that the host response is equally or more important in defining the eventual pathological outcome of infection. Systems biology has in recent years been increasingly recognised for its importance to infectious disease research. Host-virus interactions can be better understood by taking into account the dynamical molecular networks that constitute a biological system. To decipher the pathobiological mechanisms of any disease requires a deep knowledge of how multiple and concurrent signal-transduction pathways operate and are deregulated. Hence the intricacies of signalling pathways can be dissected only by system level approaches. Deciphering the host virus interactions through system biology approach reviewed High throughput techniques to understand the host pathogen interactions examined Shift from virus-centric perspective to spectrum of virus-host interactions Modeling of host-virus cross talk
Collapse
Affiliation(s)
- Sajad Ahmad Wani
- Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar 243122, India
| | - Amit Ranjan Sahu
- Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar 243122, India
| | - Shikha Saxena
- Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar 243122, India
| | - Shahid Hussain
- Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar 243122, India
| | - Aruna Pandey
- Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar 243122, India
| | - Sonam Kanchan
- Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar 243122, India
| | - Aditya Prasad Sahoo
- Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar 243122, India
| | - Bina Mishra
- Division of Biological Products, ICAR-Indian Veterinary Research Institute, Izatnagar 243122, India
| | - Ashok Kumar Tiwari
- Division of Biological Standardization, ICAR-Indian Veterinary Research Institute, Izatnagar 243122, India
| | - Bishnu Prasad Mishra
- Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar 243122, India
| | - Ravi Kumar Gandham
- Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar 243122, India
| | - Raj Kumar Singh
- Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar 243122, India
| |
Collapse
|
19
|
Gupta SK, Haigh BJ, Wheeler TT. Abundance of RNase4 and RNase5 mRNA and protein in host defence related tissues and secretions in cattle. Biochem Biophys Rep 2016; 8:261-267. [PMID: 28955965 PMCID: PMC5613968 DOI: 10.1016/j.bbrep.2016.09.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Revised: 08/26/2016] [Accepted: 09/02/2016] [Indexed: 12/14/2022] Open
Abstract
Members of the RNaseA family are present in various tissues and secretions but their function is not well understood. Some of the RNases are proposed to participate in host defence. RNase4 and RNase5 are present in cows' milk and have antimicrobial activity. However, their presence in many tissues and secretions has not been characterised. We hypothesised that these two RNases are present in a range of tissues and secretions where they could contribute to host defence. We therefore, determined the relative abundance of RNase4 and RNase5 mRNA as well as protein levels in a range of host defence related and other tissues as well as a range of secretions in cattle, using real time PCR and western blotting. The two RNases were found to be expressed in liver, lung, pancreas, mammary gland, placenta, endometrium, small intestine, seminal vesicle, salivary gland, kidney, spleen, lymph node, skin as well as testes. Corresponding proteins were also detected in many of the above tissues, as well as in seminal fluid, mammary secretions and saliva. This study provides evidence for the presence of RNase4 and RNase5 in a range of tissues and secretions, as well as some major organs in cattle. The data are consistent with the idea that these proteins could contribute to host defence in these locations. This work contributes to growing body of data suggesting that these proteins contribute to the physiology of the organism in a more complex way than acting merely as digestive enzymes. RNase4 and RNase5 are present in several tissues and secretions in cattle. mRNA and protein levels of the RNases correlate in various tissues analysed. The RNases could contribute to host defence in these tissues and secretions.
Collapse
Affiliation(s)
- Sandeep K Gupta
- Dairy Foods, AgResearch, Ruakura Research Centre, Hamilton, New Zealand
| | - Brendan J Haigh
- Dairy Foods, AgResearch, Ruakura Research Centre, Hamilton, New Zealand
| | - Thomas T Wheeler
- Dairy Foods, AgResearch, Ruakura Research Centre, Hamilton, New Zealand
| |
Collapse
|
20
|
Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B 2016; 6:287-96. [PMID: 27471669 PMCID: PMC4951582 DOI: 10.1016/j.apsb.2016.02.001] [Citation(s) in RCA: 826] [Impact Index Per Article: 103.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Revised: 01/19/2016] [Accepted: 01/26/2016] [Indexed: 02/07/2023] Open
Abstract
Exosomes are small intracellular membrane-based vesicles with different compositions that are involved in several biological and pathological processes. The exploitation of exosomes as drug delivery vehicles offers important advantages compared to other nanoparticulate drug delivery systems such as liposomes and polymeric nanoparticles; exosomes are non-immunogenic in nature due to similar composition as body׳s own cells. In this article, the origin and structure of exosomes as well as their biological functions are outlined. We will then focus on specific applications of exosomes as drug delivery systems in pharmaceutical drug development. An overview of the advantages and challenges faced when using exosomes as a pharmaceutical drug delivery vehicles will also be discussed.
Collapse
Key Words
- ALIX, ALG-2 interacting protein X
- ATPase, adenosine triphosphatase
- BBB, blood–brain barrier
- CCK-8, cell counting kit-8
- CD, cluster of differentiation
- DIL, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate
- DNA, deoxyribonucleic acid
- Drug delivery systems
- EGF, epidermal growth factor
- EGFR, epidermal growth factor receptor
- ESCRT, endosomal sorting complexes required for transport
- EV, extracellular vesicle
- EpCAM, epithelial cell adhesion molecule
- Exosomes
- Extracellular vesicles
- HEK293, human embryonic kidney cell line 293
- HIV, human immunodeficiency virus
- HMGA2, high-mobility group AT-hook protein
- HeLa, Henrietta Lacks cells
- Hsp, heat shock proteins
- IL-6, interleukin-6
- ILVs, intraluminal vesicles
- LPS, lipopolysaccharides
- MAPK-1, mitogen-activated protein kinase 1
- MHC, major histocompatibility complex
- MPS, mononuclear phagocyte system
- MVB, multi-vesicular body biogenesis
- Nanocarrier
- PBMC, peripheral blood mononuclear cells
- PD, Parkinson’s disease
- PEG, polyethylene glycol
- RNA, ribonucleic acid
- ROS, reactive oxygen species
- RPE1, retinal pigment epithelial cells 1
- TNF-α, tumor necrosis factor α
- TSG101, tumor susceptibility gene 101
- VPS4, vacuolar protein sorting-associated protein 4
- kRAS, Kirsten rat sarcoma
- mRNA, messenger RNA
- miRNA, micro RNA
- siRNA, small interference RNA
Collapse
Affiliation(s)
| | | | - Venkatareddy Nadithe
- Manchester University, College of Pharmacy, Natural & Health Sciences, Fort Wayne, IN 46845, USA
| |
Collapse
|
21
|
Nougarede N, Bisceglia H, Rozières A, Goujon C, Boudet F, Laurent P, Vanbervliet B, Rodet K, Hennino A, Nicolas JF. Nine μg intradermal influenza vaccine and 15 μg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults. Hum Vaccin Immunother 2016; 10:2713-20. [PMID: 25483667 PMCID: PMC4977438 DOI: 10.4161/hv.29695] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Intanza® 9 μg (Sanofi Pasteur), a trivalent split-virion vaccine administered by intradermal (ID) injection, was approved in Europe in 2009 for the prevention of seasonal influenza in adults 18 to 59 years. Here, we examined the immune responses induced in adults by the ID 9 μg vaccine and the standard trivalent intramuscular (IM) vaccine (Vaxigrip® 15 μg, Sanofi Pasteur). This trial was a randomized, controlled, single-center, open-label study in healthy adults 18 to 40 years of age during the 2007/8 influenza season. Subjects received a single vaccination with the ID 9 μg (n=38) or IM 15 μg (n=42) vaccine. Serum, saliva, and peripheral blood mononuclear cells were collected up to 180 days post-vaccination. Geometric mean hemagglutination inhibition titers, seroprotection rates, seroconversion rates, and pre-vaccination-to-post-vaccination ratios of geometric mean hemagglutination inhibition titers did not differ between the two vaccines. Compared with pre-vaccination, the vaccines induced similar increases in vaccine-specific circulating B cells at day 7 but did not induce significant increases in vaccine-specific memory B cells at day 180. Cell-mediated immunity to all three vaccine strains, measured in peripheral blood mononuclear cells, was high at baseline and not increased by either vaccine. Neither vaccine induced a mucosal immune response. These results show that the humoral and cellular immune responses to the ID 9 μg vaccine are similar to those to the standard IM 15 μg vaccine.
Collapse
Key Words
- BSA, bovine serum albumin
- CHMP, Committee for Medicinal Products for Human Use
- ELISA, enzyme-linked immunosorbent assay
- ELISPOT, enzyme-linked immunospot
- HI, hemagglutination inhibition
- ID, intradermal
- IM, intramuscular
- Ig, immunoglobulin
- PBMC, peripheral blood mononuclear cells
- PBS, phosphate-buffered saline
- adult
- immunogenicity
- intradermal influenza vaccine
- intramuscular vaccination
- trivalent influenza vaccine
Collapse
|
22
|
Prinsen H, van Laarhoven HWM, Pots JM, Duiveman-de Boer T, Mulder SF, van Herpen CML, Jacobs JFM, Leer JWH, Bleijenberg G, Stelma FF, Torensma R, de Vries IJM. Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue. Hum Vaccin Immunother 2016; 11:1634-40. [PMID: 25996472 PMCID: PMC4514289 DOI: 10.1080/21645515.2015.1040207] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
The aim of this study was to compare humoral and cellular immune responses to influenza vaccination in cancer survivors with and without severe symptoms of fatigue. Severely fatigued (n = 15) and non-fatigued (n = 12) disease-free cancer survivors were vaccinated against seasonal influenza. Humoral immunity was evaluated at baseline and post-vaccination by a hemagglutination inhibition assay. Cellular immunity was evaluated at baseline and post-vaccination by lymphocyte proliferation and activation assays. Regulatory T cells were measured at baseline by flow cytometry and heat-shock protein 90 alpha levels by ELISA. Comparable humoral immune responses were observed in fatigued and non-fatigued patients, both pre- and post-vaccination. At baseline, fatigued patients showed a significantly diminished cellular proliferation upon virus stimulation with strain H3N2 (1414 ± 1201 counts), and a trend in a similar direction with strain H1N1 (3025 ± 2339 counts), compared to non-fatigued patients (3099 ± 2401 and 5877 ± 4604 counts, respectively). The percentage of regulatory T lymphocytes was significantly increased (4.4 ± 2.1% versus 2.4 ± 0.8%) and significantly lower amounts of interleukin 2 were detected prior to vaccination in fatigued compared to non-fatigued patients (36.3 ± 44.3 pg/ml vs. 94.0 ± 45.4 pg/ml with strain H3N2 and 28.4 ± 44.0 pg/ml versus 74.5 ± 56.1 pg/ml with strain H1N1). Pre-vaccination heat-shock protein 90 alpha concentrations, post-vaccination cellular proliferation, and post-vaccination cytokine concentrations did not differ between both groups. In conclusion, influenza vaccination is favorable for severely fatigued cancer survivors and should be recommended when indicated. However, compared to non-fatigued cancer survivors, fatigued cancer survivors showed several significant differences in immunological reactivity at baseline, which warrants further investigation.
Collapse
Key Words
- CBT, cognitive behavior therapy
- CIS-fatigue, Checklist Individual Strength fatigue subscale
- HI, hemagglutination-inhibition
- HSP90α, human heat shock protein 90 alpha
- IFN- γ, interferon gamma
- IL-10, interleukin 10
- IL-2, interleukin 2
- IL-4, interleukin 4
- IL-5, interleukin 5
- PBMC, peripheral blood mononuclear cells
- PHA, phytohemagglutinin
- Radboudumc, Radboud University Medical Center
- Treg, regulatory T lymphocytes
- cancer
- fatigue
- immunity
- influenza
- vaccination
Collapse
Affiliation(s)
- Hetty Prinsen
- a Department of Medical Oncology; Radboud University Medical Center ; Nijmegen , the Netherlands
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Leung TF, Liu APY, Lim FS, Thollot F, Oh HML, Lee BW, Rombo L, Tan NC, Rouzier R, Friel D, De Muynck B, De Simoni S, Suryakiran P, Hezareh M, Folschweiller N, Thomas F, Struyf F. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial. Hum Vaccin Immunother 2016; 11:1689-702. [PMID: 26062002 PMCID: PMC4514190 DOI: 10.1080/21645515.2015.1050570] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
This observer-blind study (clinicaltrials.gov NCT01462357) compared the immunogenicity and safety of 2 doses of the HPV-16/18 AS04-adjuvanted vaccine (HPV-16/18(2D)) vs. 2 or 3 doses of the HPV-6/11/16/18 vaccine (HPV-6/11/16/18(2D) and HPV-6/11/16/18(3D)) in healthy girls aged 9–14 y. Girls were randomized (1:1:1) to receive HPV-16/18(2D) at months (M) 0,6 (N = 359), HPV-6/11/16/18(2D) at M0,6 (N = 358) or HPV-6/11/16/18(3D) at M0,2,6 (N = 358). The primary objective was non-inferiority/superiority of HPV-16/18 antibodies by ELISA for HPV-16/18(2D) vs. HPV-6/11/16/18(2D) at M7 in the according-to-protocol immunogenicity cohort (ATP-I) and total vaccinated cohort, respectively. Secondary objectives included non-inferiority/superiority of HPV-16/18(2D) vs. HPV-6/11/16/18(3D) at M7, non-inferiority/superiority at M12, HPV-16/18 neutralizing antibodies, frequencies of T-cells/B-cells, reactogenicity and safety. Antibody responses at M7 for HPV-16/18(2D) were superior to those for HPV-6/11/16/18(2D) and HPV-6/11/16/18(3D) (lower limit of 95% confidence interval for geometric mean titer ratio (GMR) was >1): HPV-16/18(2D)/HPV-6/11/16/18(2D) GMRs were 1.69 [1.49–1.91] for anti-HPV-16 and 4.52 [3.97–5.13] for anti-HPV-18; HPV-16/18(2D)/HPV-6/11/16/18(3D) GMRs were 1.72 [1.54–1.93] for anti-HPV-16 and 3.22 [2.82–3.68] for anti-HPV-18; p = 0.0001 for all comparisons. Non-inferiority/superiority was also demonstrated at M12. Among initially seronegative girls in the ATP-I, neutralizing antibody titers were at least 1.8-fold higher for HPV-16/18(2D) vs. HPV-6/11/16/18(2D) and HPV-6/11/16/18(3D) at M7 and M12. Frequencies of HPV-16/18-specific T-cells and B-cells were in similar ranges between groups. Reactogenicity and safety were in line with the known profile of each vaccine. In conclusion, superior HPV-16/18 antibody responses were elicited by 2 doses of the HPV-16/18 AS04-adjuvanted vaccine compared with 2 or 3 doses of the HPV-6/11/16/18 vaccine in girls (9–14 years).
Collapse
Key Words
- 2D, 2-dose
- 3D, 3-dose
- AAHS, aluminum hydroxyphosphate sulfate
- ANOVA, analysis of variance
- AS04, Adjuvant System containing 50 µg 3-O-desacyl-4 ′-monophosphoryl lipid A (MPL) adsorbed on aluminum salt (500 µg Al3+)
- ATP-I, according-to-protocol immunogenicity cohort
- CI, confidence interval
- CMI, cell-mediated immunity
- ED50, effective dose producing 50% response
- ELISA, enzyme-linked immunosorbent assay
- ELISPOT, enzyme-linked immunosorbent spot assay
- EU, ELISA unit
- GMR, geometric mean titer ratio
- GMT, geometric mean antibody titer
- HPV, human papillomavirus
- HPV-16/18(2D), 2-dose schedule of the HPV-16/18 vaccine
- HPV-6/11/16/18(2D), 2-dose schedule of the HPV-6/11/16/18 vaccine
- HPV-6/11/16/18(3D), 3-dose schedule of the HPV-6/11/16/18 vaccine
- IFNγ, interferon
- IgG, immunoglobulin G
- M, month(s)
- PBMC, peripheral blood mononuclear cells
- PBNA, pseudovirion-based neutralisation assay
- SAE, serious adverse event
- TVC, total vaccinated cohort
- VLP, virus-like particle
- administration schedule
- female adolescents
- human papillomavirus (HPV) vaccines
- immunogenicity
- pIMD, potential immune-mediated disease
- safety
- y, year(s)
Collapse
Affiliation(s)
- Ting Fan Leung
- a Department of Paediatrics ; The Chinese University of Hong Kong ; Shatin , Hong Kong
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Fenoglio D, Parodi A, Lavieri R, Kalli F, Ferrera F, Tagliamacco A, Guastalla A, Lamperti MG, Giacomini M, Filaci G. Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one. Hum Vaccin Immunother 2016; 11:838-50. [PMID: 25714118 PMCID: PMC4514186 DOI: 10.1080/21645515.2015.1012032] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Peptide540–548, peptide611–626, peptide672–686 and peptide766–780, which are derived from human telomerase, constitute the immunogenic component of the GX301 cancer vaccine. The relative immunogenicity of these peptides is unknown, thus it is unsure whether their combined use offers real advantages over single peptide stimulation. Hence, this study compared the number of specific immune responses and responders to each peptide, as well as to their mixture (meaning the co-presence of the 4 peptides in the same culture well), achieved after ex vivo stimulation of PBMC from 21, HLA-A2+ (n.11) or HLA-A2- (n.10), healthy donors. The study was performed on freshly collected PBMC (T0) and on PBMC stimulated for 10 d with single peptides or their mixture (T1). Peptide-specific immune responses were analyzed by Elispot and cytokine intracellular staining by flow cytometry. The results showed that each peptide induced specific immune responses in some subjects, with different panels of responders among the peptides. Moreover, the numbers of responses and responders to the single peptides or their mixture were comparable. Importantly, the overall number of responders to the 4 peptides was higher than to each single peptide, or to their mixture, both at T0 and T1. These data demonstrate the immunogenicity of each of the 4 GX301 telomerase peptides. Moreover, they show the advantage of multi-peptide over single peptide stimulation, providing a clear support to their combined administration in vaccination protocols. However, the data pose a warning against peptide administration as a mixture due to possible interference phenomena during antigen presentation processes.
Collapse
Affiliation(s)
- Daniela Fenoglio
- a Centre of Excellence for Biomedical Research ; University of Genoa ; Genoa , Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Yin W, Gorvel L, Zurawski S, Li D, Ni L, Duluc D, Upchurch K, Kim J, Gu C, Ouedraogo R, Wang Z, Xue Y, Joo H, Gorvel JP, Zurawski G, Oh S. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells. EBioMedicine 2016; 5:46-58. [PMID: 27077111 DOI: 10.1016/j.ebiom.2016.01.029] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Revised: 01/21/2016] [Accepted: 01/25/2016] [Indexed: 11/25/2022] Open
Abstract
Dendritic cells (DCs) are major antigen-presenting cells that can efficiently prime and cross-prime antigen-specific T cells. Delivering antigen to DCs via surface receptors is thus an appealing strategy to evoke cellular immunity. Nonetheless, which DC surface receptor to target to yield the optimal CD8+ and CD4+ T cell responses remains elusive. Herein, we report the superiority of CD40 over 9 different lectins and scavenger receptors at evoking antigen-specific CD8+ T cell responses. However, lectins (e.g., LOX-1 and Dectin-1) were more efficient than CD40 at eliciting CD4+ T cell responses. Common and distinct patterns of subcellular and intracellular localization of receptor-bound αCD40, αLOX-1 and αDectin-1 further support their functional specialization at enhancing antigen presentation to either CD8+ or CD4+ T cells. Lastly, we demonstrate that antigen targeting to CD40 can evoke potent antigen-specific CD8+ T cell responses in human CD40 transgenic mice. This study provides fundamental information for the rational design of vaccines against cancers and viral infections. Antigen delivery to DCs via CD40 is more efficient than through nine other receptors at eliciting CD8 T+ cell response. Antigen delivery via lectins (e.g., LOX-1 and Dectin-1) is more efficient than CD40 at eliciting CD4+ T cell responses.
The success of an immunotherapeutic vaccine for cancer is largely dependent on its ability to evoke potent cellular immunity. Although targeting antigens to dendritic cells (DCs) has been known to be an efficient strategy to evoke cellular immunity, which targeted receptors yield the optimal cellular immunity remained elusive. We report that targeting CD40, compared to 9 other DC receptors, results in the greatest levels of CD8+ cytotoxic T cell responses, while targeting lectins results in enhanced CD4+ helper T cell responses. The findings of this study will assist us in the rational design of immunotherapeutic vaccines against cancers.
Collapse
Key Words
- ANOVA, analysis of variance
- AP, alkaline phosphatase
- APC, antigen-presenting cells
- CD, cluster of differentiation
- CD40
- CFSE, carboxyfluorescein succinimidyl ester
- CTL, cytotoxic T lymphocyte
- Coh, cohesin
- Cross-presentation
- DC, dendritic cell
- Dendritic cell
- Doc, dockerin
- EEA1, early endosome antigen 1
- ELISA, enzyme-linked immunosorbent assay
- ELISpot, enzyme-linked immunospot
- Flu.M1, influenza virus matrix protein 1
- GM-CSF, granulocyte-macrophage colony-stimulating factor
- HA1, hemagglutinin subunit 1
- HLA, human leukocyte antigen
- HPV, human papillomavirus
- HRP, horseradish peroxidase
- IFN, interferon
- IL, interleukin
- JaCoP, Just another Colocalization Plugin
- LAMP-1, lysosomal-associated membrane protein 1
- Lectins
- MART-1, melanoma antigen recognized by T cells 1
- MHC, major histocompatibility complex
- Mo-DC, monocyte-derived dendritic cell
- NHP, non-human primate
- NP, nucleoprotein
- PBMC, peripheral blood mononuclear cells
- PBS, phosphate-buffered saline
- PSA, prostate specific antigen
- Poly(I:C), polyinosinic:polycytidylic acid
- TLR, toll-like receptor
- TMB, 3,3′,5,5′-tetramethylbenzidine
- TNF, tumor necrosis factor
- Vaccine
- hCD40Tg, human CD40 transgenic
- i.p., intraperitoneal(ly)
- mAb, monoclonal antibody
- mDC, myeloid dendritic cell
- pDC, plasmacytoid dendritic cell
- s.c., subcutaneous(ly)
Collapse
|
26
|
Ponte C, Peres L, Marinho S, Lima J, Siqueira M, Pedro T, De Luca P, Cascabulho C, Castello-Branco LR, Antas PRZ. In vitro T-cell profile induced by BCG Moreau in healthy Brazilian volunteers. Hum Vaccin Immunother 2015; 11:450-7. [PMID: 25483636 DOI: 10.4161/21645515.2014.970954] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Tuberculosis (TB) remains the world's leading cause of morbidity and mortality. Although Mycobacterium bovis bacillus Calmette-Guérin (BCG) is the only vaccine currently in use, its efficacy is highly variable. It has been suggested that early antigenic presentation is a pivotal event leading to a better immune response in TB vaccine models. To investigate this further, we compared in vitro cell-mediated immune responses in the context of early sensitization with TB (i.e. healthy adults vaccinated with BCG when they were young, HD; n = 25) to those in its absence (i.e., newborns with naïve immunity to TB, UV; n = 10) by challenging mononuclear cells with BCG Moreau. After 48 hours, CD4+ and CD8+ T cells were harvested from both groups and stained for PD-1/CD25/ FOXP3. In addition, supernatants were assayed for a broad range of cytokines using an array system. The HD group showed robust reactivity to Protein Purified Derivative and BCG while the naïve, UV group did not. Similarly, in terms of PD-1 expression and Treg cells (CD4+/CD25high(+)/FOXP3+), only the HD group showed higher levels in CD4 lymphocytes. Otherwise, only the UV group showed expression of CD25dim+ as an activation marker dependent on BCG infection. In terms of cytokines, the HD group showed higher levels of Th1 (IL-2/TNF-α/IFN-γ) and regulatory (IL-10) profiles, with monocytes, but not Tr1 cells, acting as the main source of IL-10. Taken together, our results highlight critical roles of early sensitization with TB in mounting cell-mediated immune responses.
Collapse
Key Words
- BCG vaccine
- BCG, bacillus calmette-guérin
- CBA, cytometric beads array kit
- CBMC, cord blood mononuclear cells
- ELISA, enzyme-linked immunosorbent assay
- ELISPOT, enzyme linked immunospot
- FACS, fluorescence activating cell sorting
- HD, healthy donor
- HIV, human immunodeficiency virus
- HLA, human leukocyte antigen
- PBMC, peripheral blood mononuclear cells
- PHA, phytohaemaglutinin
- PPD, protein purified derivative
- TB, tuberculosis
- UV, umbilical vein
- cytokine
- iNKT, invariant natural killer T cells
- lymphocyte
- phenotyping
- tuberculosis
Collapse
Affiliation(s)
- C Ponte
- a Laboratório de Imunologia Clínica; Instituto Oswaldo Cruz ; Fiocruz , Rio de Janeiro , Brazil
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Rovetta AI, Peña D, Hernández Del Pino RE, Recalde GM, Pellegrini J, Bigi F, Musella RM, Palmero DJ, Gutierrez M, Colombo MI, García VE. IFNG-mediated immune responses enhance autophagy against Mycobacterium tuberculosis antigens in patients with active tuberculosis. Autophagy 2015; 10:2109-21. [PMID: 25426782 DOI: 10.4161/15548627.2014.981791] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Protective immunity against Mycobacterium tuberculosis (Mtb) requires IFNG. Besides, IFNG-mediated induction of autophagy suppresses survival of virulent Mtb in macrophage cell lines. We investigated the contribution of autophagy to the defense against Mtb antigen (Mtb-Ag) in cells from tuberculosis patients and healthy donors (HD). Patients were classified as high responders (HR) if their T cells produced significant IFNG against Mtb-Ag; and low responders (LR) when patients showed weak or no T cell responses to Mtb-Ag. The highest autophagy levels were detected in HD cells whereas the lowest quantities were observed in LR patients. Interestingly, upon Mtb-Ag stimulation, we detected a positive correlation between IFNG and MAP1LC3B-II/LC3-II levels. Actually, blockage of Mtb-Ag-induced IFNG markedly reduced autophagy in HR patients whereas addition of limited amounts of IFNG significantly increased autophagy in LR patients. Therefore, autophagy collaborates with human immune responses against Mtb in close association with specific IFNG secreted against the pathogen.
Collapse
Key Words
- AG, antigen
- ATG, autophagy-related
- FBS, fetal bovine serum
- GAPDH, glyceraldehyde-3-phosphate dehydrogenase
- GTP, guanosine triphosphate
- HD, healthy donors
- HR TB, high-responder tuberculosis patient
- IFNG
- IFNG, interferon gamma
- IL, Interleukin
- LC3, microtubule-associated protein 1A/1B-light chain 3
- LR TB, low-responder tuberculosis patients
- Mtb-Ag, Mycobacterium tuberculosis antigen
- PBMC, peripheral blood mononuclear cells
- PBS, phosphate-buffered saline
- SLAM, signaling lymphocytic activation molecule
- TB, tuberculosis
- Th, T helper
- autophagy
- cytokines
- defense
- immune response
- mAb, monoclonal antibody
- patients
- rIFNG, recombinant IFNG
- tuberculosis
Collapse
Affiliation(s)
- Ana I Rovetta
- a Departamento de Química Biológica; Facultad de Ciencias Exactas y Naturales; Universidad de Buenos Aires (UBA) ; Buenos Aires , Argentina
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Di Sante G, Tolusso B, Fedele AL, Gremese E, Alivernini S, Nicolò C, Ria F, Ferraccioli G. Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid Arthritis. EBioMedicine 2015; 2:2037-45. [PMID: 26844284 PMCID: PMC4703746 DOI: 10.1016/j.ebiom.2015.11.019] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2015] [Revised: 11/10/2015] [Accepted: 11/10/2015] [Indexed: 12/29/2022] Open
Abstract
Rheumatoid arthritis (RA) is characterized by chronic joint inflammation and associates with HLA-DRB1*04. The Collagen IIp261-273-specific T cell repertoire in the peripheral blood of DR4 + patients at the onset of the disease shows a restricted TCR-beta chain usage among which the most frequent is TRBV25. To define whether this group of DR4-restricted collagen-specific shared T cell could represent markers of active-severe disease and response to therapy, 90 subjects affected by early-RA were enrolled in the study; peripheral blood mononuclear cells were cultured with or without the human collagen II peptide p261-273 and were examined by immunoscope analysis for the usage of the previously identified shared TCR-beta chains. We report that the presence of T cells carrying rearrangement TRBV25 associated with HLA-DR haplotype and disease activity. HLA-DRB1* haplotypes 04–04, 04–01 and 04–11 were significantly associated with usage of TRBV25, higher disease activity at the onset of disease and poor response to DMARDs. Finally, the HLA-DRB1* haplotype appeared complementary with current serologic tools to predict good and poor responders in a treat to target strategy. The data reported here offer clues to predict the course of the disease and to foresee personalized treatments in RA patients. In DR4 + RA patients disease activity is associated with detection of Collagen261-273-specific T cells carrying TRBV25. HLA-DR 04/04, 04/01 and 04/11 alleles were associated with TRBV25, DAS at the onset, and poor response to DMARDs. These findings could lead to tailor the treatment in the subgroup of patients with an active refractory disease.
In the era of costly medical care with monoclonal antibodies and new molecules, and of an increasing request of a personalized medicine, a relevant socio-economic problem in the management of Rheumatoid Arthritis patients is the possible identification of the subgroups of poor responders to treatment. Our study aimed to detect the refractory active patients using an HLA-DR test (available in most hospital centers) combined with a relatively new biomarker of active disease expressed on the cell surface of autoreactive T cells. These tests appear complementary tools to identify the best and the poor responders to a “treat to target strategy”.
Collapse
Key Words
- ACPA
- ACPA, anti-cyclic citrullinated peptide antibodies
- APCs, antigen presenting cells
- CDR3, complementarity-determining region 3
- CRP, C-reactive protein
- Clonotypes
- Coll261-273, human collagen derived peptide
- DAS, disease activity score
- Disease activity
- ERA, early rheumatoid arthritis
- ESR, erythrocyte sedimentation rate
- GWAS, genome wide association studies
- HAQ, Health Assessment Questionnaire
- HLA, histocompatibility leucocyte antigen
- HLA-DRB1
- MHC, major histocompatibility complex
- PBMC, peripheral blood mononuclear cells
- RF, rheumatoid factor
- RT-PCR, reverse transcription polymerase chain reaction
- SJC, swollen joint count
- SNP, single nucleotide polymorphism
- TCR, T cell receptor
- TJC, tender joint count
- TRBJ, junctional beta chain gene of TCR
- TRBV 25
- TRBV, variable beta chain gene of TCR
Collapse
Affiliation(s)
- Gabriele Di Sante
- Institute of General Pathology, Catholic University of the Sacred Heart, Rome, Italy
- Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
| | - Barbara Tolusso
- Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
| | - Anna Laura Fedele
- Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
| | - Elisa Gremese
- Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
| | - Stefano Alivernini
- Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
| | - Chiara Nicolò
- Institute of General Pathology, Catholic University of the Sacred Heart, Rome, Italy
| | - Francesco Ria
- Institute of General Pathology, Catholic University of the Sacred Heart, Rome, Italy
| | - Gianfranco Ferraccioli
- Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
- Corresponding author.
| |
Collapse
|
29
|
Delgado E, Perez-Basterrechea M, Suarez-Alvarez B, Zhou H, Revuelta EM, Garcia-Gala JM, Perez S, Alvarez-Viejo M, Menendez E, Lopez-Larrea C, Tang R, Zhu Z, Hu W, Moss T, Guindi E, Otero J, Zhao Y. Modulation of Autoimmune T-Cell Memory by Stem Cell Educator Therapy: Phase 1/2 Clinical Trial. EBioMedicine 2015; 2:2024-36. [PMID: 26844283 DOI: 10.1016/j.ebiom.2015.11.003] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2015] [Revised: 10/29/2015] [Accepted: 11/03/2015] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease that causes a deficit of pancreatic islet β cells. The complexities of overcoming autoimmunity in T1D have contributed to the challenges the research community faces when devising successful treatments with conventional immune therapies. Overcoming autoimmune T cell memory represents one of the key hurdles. METHODS In this open-label, phase 1/phase 2 study, Caucasian T1D patients (N = 15) received two treatments with the Stem Cell Educator (SCE) therapy, an approach that uses human multipotent cord blood-derived multipotent stem cells (CB-SCs). SCE therapy involves a closed-loop system that briefly treats the patient's lymphocytes with CB-SCs in vitro and returns the "educated" lymphocytes (but not the CB-SCs) into the patient's blood circulation. This study is registered with ClinicalTrials.gov, NCT01350219. FINDINGS Clinical data demonstrated that SCE therapy was well tolerated in all subjects. The percentage of naïve CD4(+) T cells was significantly increased at 26 weeks and maintained through the final follow-up at 56 weeks. The percentage of CD4(+) central memory T cells (TCM) was markedly and constantly increased at 18 weeks. Both CD4(+) effector memory T cells (TEM) and CD8(+) TEM cells were considerably decreased at 18 weeks and 26 weeks respectively. Additional clinical data demonstrated the modulation of C-C chemokine receptor 7 (CCR7) expressions on naïve T, TCM, and TEM cells. Following two treatments with SCE therapy, islet β-cell function was improved and maintained in individuals with residual β-cell function, but not in those without residual β-cell function. INTERPRETATION Current clinical data demonstrated the safety and efficacy of SCE therapy in immune modulation. SCE therapy provides lasting reversal of autoimmune memory that could improve islet β-cell function in Caucasian subjects. FUNDING Obra Social "La Caixa", Instituto de Salud Carlos III, Red de Investigación Renal, European Union FEDER Funds, Principado de Asturias, FICYT, and Hackensack University Medical Center Foundation.
Collapse
Key Words
- AIRE, autoimmune regulator
- Autoimmunity
- CB-SCs, human cord blood-derived multipotent stem cells
- CCR7, C–C chemokine receptor 7
- Cord blood stem cell
- HLA, human leukocyte antigen
- HbA1C, glycated hemoglobin
- IL, interleukin
- Immune modulation
- M2, muscarinic acetylcholine receptor 2
- MLR, mixed leukocyte reactions
- MNC, mononuclear cells
- Memory T cells
- OGTT, oral glucose tolerance test
- PBMC, peripheral blood mononuclear cells
- R, responder
- S, stimulator
- SCE, Stem Cell Educator
- T1D, type 1 diabetes
- TCM, central memory T cells
- TCR, T-cell receptor
- TEM, effector memory T cells
- TGF-β1, transforming growth factor-β1
- Th, helper T cell
- Tregs, regulatory T cells
- Type 1 diabetes
Collapse
|
30
|
Pichavant M, Sharan R, Le Rouzic O, Olivier C, Hennegrave F, Rémy G, Pérez-Cruz M, Koné B, Gosset P, Just N, Gosset P. IL-22 Defect During Streptococcus pneumoniae Infection Triggers Exacerbation of Chronic Obstructive Pulmonary Disease. EBioMedicine 2015; 2:1686-96. [PMID: 26870795 PMCID: PMC4740310 DOI: 10.1016/j.ebiom.2015.09.040] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2015] [Revised: 09/22/2015] [Accepted: 09/23/2015] [Indexed: 12/22/2022] Open
Abstract
Progression of chronic obstructive pulmonary disease (COPD) is linked to episodes of exacerbations caused by bacterial infections due to Streptococcus pneumoniae. Our objective was to identify during COPD, factors of susceptibility to bacterial infections among cytokine network and their role in COPD exacerbations. S. pneumoniae was used to sub-lethally challenge mice chronically exposed to air or cigarette smoke (CS) and to stimulate peripheral blood mononuclear cells (PBMC) from non-smokers, smokers and COPD patients. The immune response and the cytokine production were evaluated. Delayed clearance of the bacteria and stronger lung inflammation observed in infected CS-exposed mice were associated with an altered production of IL-17 and IL-22 by innate immune cells. This defect was related to a reduced production of IL-1β and IL-23 by antigen presenting cells. Importantly, supplementation with recombinant IL-22 restored bacterial clearance in CS-exposed mice and limited lung alteration. In contrast with non-smokers, blood NK and NKT cells from COPD patients failed to increase IL-17 and IL-22 levels in response to S. pneumoniae, in association with a defect in IL-1β and IL-23 secretion. This study identified IL-17 and IL-22 as susceptibility factors in COPD exacerbation. Therefore targeting such cytokines could represent a potent strategy to control COPD exacerbation.
Collapse
Key Words
- AM, alveolar macrophages
- APC, antigen presenting cells
- BAL, broncho-alveolar lavage
- Bacterial infection
- CFU, colony forming unit
- COPD, chronic obstructive pulmonary disease
- CS, cigarette smoke
- Chronic obstructive pulmonary disease
- DC, dendritic cells
- IL-22
- Innate immunity
- NK, natural killer cells
- NKT, natural killer T cells
- PBMC, peripheral blood mononuclear cells
- Sp, Streptococcus pneumoniae
Collapse
Affiliation(s)
- Muriel Pichavant
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
| | - Riti Sharan
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
| | - Olivier Le Rouzic
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
- Service de Pneumologie, Hôpital Calmette, CHRU, Lille, France
| | - Cécile Olivier
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
- Service de Pneumologie, Hôpital Calmette, CHRU, Lille, France
| | - Florence Hennegrave
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
- Service de Pneumologie, Hôpital Calmette, CHRU, Lille, France
| | - Gaëlle Rémy
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
| | - Magdiel Pérez-Cruz
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
| | - Bachirou Koné
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
| | - Pierre Gosset
- Service d'Anatomo-Pathologie, Hôpital Saint Vincent de Paul, Lille, France
| | - Nicolas Just
- Service de Pneumologie, Hôpital Victor Provo, Roubaix, France
| | - Philippe Gosset
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
| |
Collapse
|
31
|
Einstein MH, Levin MJ, Chatterjee A, Chakhtoura N, Takacs P, Catteau G, Dessy FJ, Moris P, Lin L, Struyf F, Dubin G. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study. Hum Vaccin Immunother 2015; 10:3455-65. [PMID: 25483700 PMCID: PMC4514093 DOI: 10.4161/hv.36117] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
We previously reported higher anti-HPV-16 and -18 immune responses induced by HPV-16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after completion of full vaccination series) in women aged 18–45 y in an observer-blind study NCT00423046; the differences of immune response magnitudes were maintained up to Month 24. Here we report follow-up data through Month 48. At Month 48, in according-to-protocol cohort for immunogenicity (seronegative and DNA-negative for HPV type analyzed at baseline), geometric mean titers of serum neutralizing antibodies were 2.0- to 5.2-fold higher (HPV-16) and 8.6- to 12.8-fold higher (HPV-18) in HPV-16/18 vaccine group than in HPV-6/11/16/18 vaccine group. The majority of women in both vaccine groups remained seropositive for HPV-16. The same trend was observed for HPV-18 in HPV-16/18 vaccine group; however, seropositivity rates in HPV-6/11/16/18 vaccine group decreased considerably, particularly in the older age groups. In the total vaccinated cohort (regardless of baseline serological and HPV-DNA status), anti-HPV-16 and -18 neutralizing antibody levels induced by HPV-16/18 vaccine were higher than those induced by HPV-6/11/16/18 vaccine. CD4+ T-cell response for HPV-16 and HPV-18 was higher in HPV-16/18 vaccine group than in HPV-6/11/16/18 vaccine group. Memory B-cell responses appeared similar between vaccine groups. Both vaccines were generally well tolerated. Overall, the higher immune response observed with the HPV-16/18 vaccine was maintained up to Month 48. A head-to-head study incorporating clinical endpoints would be required to confirm whether the observed differences in immune response between the vaccines influence the duration of protection they provided.
Collapse
Key Words
- 50 μg) adsorbed on aluminum salt (500 μg Al(OH)3)
- ANOVA, analysis of variance
- AS04, Adjuvant System containing 3-O-desacyl-4’-monophosphoryl lipid A (MPL
- ATP, according-to-protocol
- CI, confidence interval
- CMI, cell-mediated immune
- CVS, cervicovaginal secretion
- Cervarix®
- ED50, effective dose producing 50% response
- ELISA, enzyme-linked immunosorbent assay
- GM, geometric mean
- GMR, geometric mean (titer) ratio
- GMT, geometric mean titer
- Gardasil®
- HPA, Health Protection Agency
- HPV, human papillomavirus
- IgG, immunoglobulin G
- MSC, medically significant condition
- NOAD, new onset autoimmune disease
- NOCD, new onset chronic disease
- PBMC, peripheral blood mononuclear cells
- PBNA, pseudovirion-based neutralization assay
- SAE, serious adverse event
- TVC, total vaccinated cohort
- VLP, virus-like particle
- human papillomavirus
- immunogenicity
- nAb(s), neutralizing antibody(ies)
- safety
Collapse
Affiliation(s)
- Mark H Einstein
- a Montefiore Medical Center; Albert Einstein College of Medicine; Department of Obstetrics & Gynecology and Women's Health ; Bronx , NY USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Dayan GH, Galán-Herrera JF, Forrat R, Zambrano B, Bouckenooghe A, Harenberg A, Guy B, Lang J. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico. Hum Vaccin Immunother 2015; 10:2853-63. [PMID: 25483647 PMCID: PMC5443102 DOI: 10.4161/21645515.2014.972131] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Several ChimeriVax-Dengue (CYD)-based vaccination strategies were investigated as potential alternatives to vaccination with tetravalent CYD vaccine (CYD-TDV) in this phase IIa trial conducted in 2008–9 in 150 healthy adults. Participants were randomized and vaccinated on D0 and D105 (± 15 days). One group received bivalent CYD vaccine against serotypes 1 and 3 (CYD-1;3) on day 0 and CYD-2;4 on day 105 (±15 days). Two groups received an injection at each timepoint of a tetravalent blend of CYD-1;3;4 and a VERO cell derived, live attenuated vaccine against serotype 2 (VDV-2), or the reference CYD-TDV. A fourth group received Japanese encephalitis (JE) vaccine on days -14, -7 and 0, followed by CYD-TDV on day 105. Viraemia was infrequent in all groups. CYD-4 viraemia was most frequent after tetravalent vaccination, while CYD-3 viraemia was most frequent after the first bivalent vaccination. Immunogenicity as assessed by 50% plaque reduction neutralisation test on D28 was comparable after the first injection of either tetravalent vaccine, and increased after the second injection, particularly with the blended CYD-1;3;4/ VDV-2 vaccine. In the bivalent vaccine group, immune response against serotype 3 was highest and the second injection elicited a low immune response against CYD 2 and 4. Immune responses after the first injection of CYD-TDV in the JE-primed group were in general higher than after the first injection in the other groups. All tested regimens were well tolerated without marked differences between groups. Bivalent vaccination showed no advantage in terms of immunogenicity. Clinical trial registration number: NCT00740155
Collapse
Key Words
- ADE, antibody-dependent enhancement
- AE, adverse event
- ALT, aspartate aminotransferase
- AST, alanine aminotransferase
- CBA, cytometric bead array
- CI, confidence interval
- CPK, creatine phosphokinase
- CYD-TDV, CYD tetravalent dengue vaccine
- GMT, geometric mean titres
- ICS, intracellular cytokine staining
- IFN, interferon
- JE, Japanese encephalitis
- Japanese encephalitis
- LLOQ, lower limit of quantitation
- MOI, multiplicity of infection
- MedDRA, medical dictionary for regulatory activities
- PBMC, peripheral blood mononuclear cells
- PFU, plaque forming unit
- PRNT, plaque reduction neutralization test
- RT-PCR, reverse transcriptase-polymerase chain reaction
- TCID, tissue culture infectious dose
- VDV, vero-cell adapted attenuated dengue vaccine
- YF, yellow fever
- dengue
- flavivirus
- immunogenicity
- safety
- vaccine
Collapse
Affiliation(s)
- Gustavo H Dayan
- a Research and Development Department ; Sanofi Pasteur ; Swiftwater , PA USA
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Bernardo D, Durant L, Mann ER, Bassity E, Montalvillo E, Man R, Vora R, Reddi D, Bayiroglu F, Fernández-Salazar L, English NR, Peake ST, Landy J, Lee GH, Malietzis G, Siaw YH, Murugananthan AU, Hendy P, Sánchez-Recio E, Phillips RK, Garrote JA, Scott P, Parkhill J, Paulsen M, Hart AL, Al-Hassi HO, Arranz E, Walker AW, Carding SR, Knight SC. Chemokine (C-C Motif) Receptor 2 Mediates Dendritic Cell Recruitment to the Human Colon but Is Not Responsible for Differences Observed in Dendritic Cell Subsets, Phenotype, and Function Between the Proximal and Distal Colon. Cell Mol Gastroenterol Hepatol 2015; 2:22-39.e5. [PMID: 26866054 PMCID: PMC4705905 DOI: 10.1016/j.jcmgh.2015.08.006] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2015] [Accepted: 08/21/2015] [Indexed: 01/28/2023]
Abstract
BACKGROUND & AIMS Most knowledge about gastrointestinal (GI)-tract dendritic cells (DC) relies on murine studies where CD103+ DC specialize in generating immune tolerance with the functionality of CD11b+/- subsets being unclear. Information about human GI-DC is scarce, especially regarding regional specifications. Here, we characterized human DC properties throughout the human colon. METHODS Paired proximal (right/ascending) and distal (left/descending) human colonic biopsies from 95 healthy subjects were taken; DC were assessed by flow cytometry and microbiota composition assessed by 16S rRNA gene sequencing. RESULTS Colonic DC identified were myeloid (mDC, CD11c+CD123-) and further divided based on CD103 and SIRPα (human analog of murine CD11b) expression. CD103-SIRPα+ DC were the major population and with CD103+SIRPα+ DC were CD1c+ILT3+CCR2+ (although CCR2 was not expressed on all CD103+SIRPα+ DC). CD103+SIRPα- DC constituted a minor subset that were CD141+ILT3-CCR2-. Proximal colon samples had higher total DC counts and fewer CD103+SIRPα+ cells. Proximal colon DC were more mature than distal DC with higher stimulatory capacity for CD4+CD45RA+ T-cells. However, DC and DC-invoked T-cell expression of mucosal homing markers (β7, CCR9) was lower for proximal DC. CCR2 was expressed on circulating CD1c+, but not CD141+ mDC, and mediated DC recruitment by colonic culture supernatants in transwell assays. Proximal colon DC produced higher levels of cytokines. Mucosal microbiota profiling showed a lower microbiota load in the proximal colon, but with no differences in microbiota composition between compartments. CONCLUSIONS Proximal colonic DC subsets differ from those in distal colon and are more mature. Targeted immunotherapy using DC in T-cell mediated GI tract inflammation may therefore need to reflect this immune compartmentalization.
Collapse
Key Words
- AMOVA, analysis of molecular variance
- CCL, chemokine (C-C motif) ligand
- CCR, chemokine (C-C motif) receptor
- CCR2
- CFSE, 5-carboxy fluorescein diacetate succinimidyl ester
- DC, dendritic cells
- DL, detection limit
- Dendritic Cells
- Distal Colon
- FACS, fluorescence-activated cell sorting
- FITC, fluorescein isothiocyanate
- GI, gastrointestinal
- Human Gastrointestinal Tract
- IL, interleukin
- ILT3, Ig-like transcript 3
- LPMC, lamina propria mononuclear cells
- Microbiota
- Mφ, macrophages
- PBMC, peripheral blood mononuclear cells
- PCR, polymerase chain reaction
- Proximal Colon
- RALDH2, retinaldehyde dehydrogenase type 2
- SIRPα, signal regulatory protein α
- SPB, sodium phosphate buffer
- Treg, regulatory T-cells
- mDC, myeloid dendritic cell
- pDC, plasmacytoid dendritic cell
Collapse
Affiliation(s)
- David Bernardo
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom
| | - Lydia Durant
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom
| | - Elizabeth R. Mann
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom,Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
| | - Elizabeth Bassity
- Gut Health and Food Safety Programme, Institute of Food Research, Norwich, United Kingdom
| | - Enrique Montalvillo
- Mucosal Immunology Group, Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid–CSIC, Valladolid, Spain
| | - Ripple Man
- St. Mark’s Hospital, North West London Hospitals NHS Trust, Harrow, United Kingdom
| | - Rakesh Vora
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom,St. Mark’s Hospital, North West London Hospitals NHS Trust, Harrow, United Kingdom
| | - Durga Reddi
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom
| | - Fahri Bayiroglu
- Department of Physiology, Faculty of Medicine, Yildirim Beyazit University, Ankara, Turkey,Faculty of Farmacy, Agri İbrahim Cecen University, Agri, Turkey
| | - Luis Fernández-Salazar
- Gastroenterology Service, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | - Nick R. English
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom
| | - Simon T.C. Peake
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom,St. Mark’s Hospital, North West London Hospitals NHS Trust, Harrow, United Kingdom
| | - Jon Landy
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom,St. Mark’s Hospital, North West London Hospitals NHS Trust, Harrow, United Kingdom
| | - Gui H. Lee
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom,St. Mark’s Hospital, North West London Hospitals NHS Trust, Harrow, United Kingdom
| | - George Malietzis
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom,St. Mark’s Hospital, North West London Hospitals NHS Trust, Harrow, United Kingdom
| | - Yi Harn Siaw
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom,St. Mark’s Hospital, North West London Hospitals NHS Trust, Harrow, United Kingdom
| | - Aravinth U. Murugananthan
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom,St. Mark’s Hospital, North West London Hospitals NHS Trust, Harrow, United Kingdom
| | - Phil Hendy
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom,St. Mark’s Hospital, North West London Hospitals NHS Trust, Harrow, United Kingdom
| | - Eva Sánchez-Recio
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom
| | - Robin K.S. Phillips
- St. Mark’s Hospital, North West London Hospitals NHS Trust, Harrow, United Kingdom
| | - Jose A. Garrote
- Mucosal Immunology Group, Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid–CSIC, Valladolid, Spain,Genetics and Molecular Biology Department, Clinical Laboratory Service, Hospital Universitario Rio Hortega, Valladolid, Spain
| | - Paul Scott
- Pathogen Genomics Group, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, United Kingdom
| | - Julian Parkhill
- Pathogen Genomics Group, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, United Kingdom
| | - Malte Paulsen
- National Heart and Lung Institute, Imperial College London, London
| | - Ailsa L. Hart
- St. Mark’s Hospital, North West London Hospitals NHS Trust, Harrow, United Kingdom
| | - Hafid O. Al-Hassi
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom
| | - Eduardo Arranz
- St. Mark’s Hospital, North West London Hospitals NHS Trust, Harrow, United Kingdom
| | - Alan W. Walker
- Pathogen Genomics Group, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, United Kingdom,Microbiology Group, Rowett Institute of Nutrition and Health, University of Aberdeen, Aberdeen, United Kingdom
| | - Simon R. Carding
- Gut Health and Food Safety Programme, Institute of Food Research, Norwich, United Kingdom,Norwich Medical School, University of East Anglia, Norwich, United Kingdom
| | - Stella C. Knight
- Antigen Presentation Research Group, Imperial College London, Harrow, United Kingdom,Correspondence Address correspondence to: Stella C. Knight, PhD, Antigen Presentation Research Group, Imperial College London, Northwick Park and St. Mark’s Campus, Watford Road, Harrow, HA1 3UJ, United Kingdom. fax: +44 (0) 20 8869 3532.Antigen Presentation Research GroupImperial College LondonNorthwick Park and St. Mark’s Campus, Watford RoadHarrowHA1 3UJUnited Kingdom
| |
Collapse
|
34
|
Lade JM, To EE, Hendrix CW, Bumpus NN. Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner. EBioMedicine 2015; 2:1145-52. [PMID: 26501112 PMCID: PMC4588390 DOI: 10.1016/j.ebiom.2015.07.008] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Revised: 07/01/2015] [Accepted: 07/02/2015] [Indexed: 11/19/2022] Open
Abstract
Tenofovir (TFV) is used in combination with other antiretroviral drugs for human immunodeficiency virus (HIV) treatment and prevention. TFV requires two phosphorylation steps to become pharmacologically active; however, the kinases that activate TFV in cells and tissues susceptible to HIV infection have yet to be identified. Peripheral blood mononuclear cells (PBMC), vaginal, and colorectal tissues were transfected with siRNA targeting nucleotide kinases, incubated with TFV, and TFV-monophosphate (TFV-MP) and TFV-diphosphate (TFV-DP) were measured using mass spectrometry–liquid chromatography. Adenylate kinase 2 (AK2) performed the first TFV phosphorylation step in PBMC, vaginal, and colorectal tissues. Interestingly, both pyruvate kinase isozymes, muscle (PKM) or liver and red blood cell (PKLR), were able to phosphorylate TFV-MP to TFV-DP in PBMC and vaginal tissue, while creatine kinase, muscle (CKM) catalyzed this conversion in colorectal tissue. In addition, next-generation sequencing of the Microbicide Trials Network MTN-001 clinical samples detected 71 previously unreported genetic variants in the genes encoding these kinases. In conclusion, our results demonstrate that TFV is activated in a compartment-specific manner. Further, genetic variants have been identified that could negatively impact TFV activation, thereby compromising TFV efficacy in HIV treatment and prevention. The anti-HIV drug tenofovir is activated in a tissue-specific manner. AK2 phosphorylates tenofovir to tenofovir-monophosphate in PBMC, vagina, and colon. PKM, PKLR phosphorylate tenofovir-monophosphate to diphosphate in PBMC and vagina. CKM phosphorylates tenofovir-monophosphate to diphosphate in colon. Because these enzymes are polymorphic and may be dysfunctional in some individuals, these findings suggest that tenofovir-based HIV PrEP may not be protective for all individuals.
Collapse
Key Words
- AK2, adenylate kinase 2
- CKM, creatine kinase, muscle
- GUK1, guanylate kinase 1
- HIV
- HIV pre-exposure prophylaxis
- HIV, human immunodeficiency virus
- MTN-001, Microbicide Trials Network Study MTN-001
- Microbicide Trials Network study MTN-001
- NME1, NME/NM23 nucleoside diphosphate kinase 1
- Nucleotide kinases
- PBMC, peripheral blood mononuclear cells
- PKLR, pyruvate kinase, liver and red blood cell
- PKM, pyruvate kinase, muscle
- PrEP, pre-exposure prophylaxis
- SNV, single-nucleotide variant
- TFV, tenofovir
- TFV-DP, tenofovir-diphosphate
- TFV-MP, tenofovir-monophosphate
- Targeted next-generation sequencing
- Tenofovir activation
Collapse
Affiliation(s)
- Julie M Lade
- Department of Pharmacology & Molecular Sciences, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Biophysics 307, Baltimore, MD 21205, USA ; Department of Medicine (Division of Clinical Pharmacology), Johns Hopkins University School of Medicine, 725 North Wolfe Street, Biophysics 307, Baltimore, MD 21205, USA
| | - Elaine E To
- Department of Pharmacology & Molecular Sciences, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Biophysics 307, Baltimore, MD 21205, USA ; Department of Medicine (Division of Clinical Pharmacology), Johns Hopkins University School of Medicine, 725 North Wolfe Street, Biophysics 307, Baltimore, MD 21205, USA
| | - Craig W Hendrix
- Department of Pharmacology & Molecular Sciences, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Blalock 569, Baltimore, MD 21287, USA ; Department of Medicine (Division of Clinical Pharmacology), Johns Hopkins University School of Medicine, 600 North Wolfe Street, Blalock 569, Baltimore, MD 21287, USA
| | - Namandjé N Bumpus
- Department of Pharmacology & Molecular Sciences, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Biophysics 307, Baltimore, MD 21205, USA ; Department of Medicine (Division of Clinical Pharmacology), Johns Hopkins University School of Medicine, 725 North Wolfe Street, Biophysics 307, Baltimore, MD 21205, USA
| |
Collapse
|
35
|
Werter IM, Schneiders FL, Scotet E, Verheul HMW, de Gruijl TD, van der Vliet HJ. Vγ9Vδ2-T cells as antigen presenting cells for iNKT cell based cancer immunotherapy. Oncoimmunology 2015; 3:e955343. [PMID: 25941612 DOI: 10.4161/21624011.2014.955343] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2014] [Accepted: 07/28/2014] [Indexed: 11/19/2022] Open
Abstract
CD1d-restricted invariant natural killer T cells (iNKT) constitute an important immunoregulatory T-cell subset involved in the induction of antitumor immune responses. Here, we provide a view on the recent observation that Vγ9Vδ2-T cells, through trogocytosis of CD1d-containing membrane fragments, have the capacity to act as antigen presenting cells for iNKT.
Collapse
Key Words
- APC
- APC, antigen presenting cells
- Ag, antigens
- BTN, butyrophilin
- BrHPP, bromohydrin pyrophosphate
- CD, Cluster of differentiation
- CD1d
- DN, double negative
- GM-CSF, granulocyte-macrophage colony-stimulating factor
- IFNγ, interferon γ
- IL, interleukine
- IPP, isopentenyl pyrophosphate
- MHC, major histocompatibility complex
- NK, natural killer cells
- PBMC, peripheral blood mononuclear cells
- TNFα, tumor necrosis factor α
- Th1, Type 1 T helper
- Th2, Type 2 T helper
- Vγ9Vδ2-T cells
- i.v., intravenous
- iNKT
- iNKT, invariant natural killer T cells
- moDC, monocyte derived dendritic cells
- pAg, phosphoantigens
- trogocytosis
- α-GalCer, α-galactosylceramide
Collapse
Affiliation(s)
- Inge M Werter
- Department of Medical Oncology; VU University Medical Center ; Amsterdam, The Netherlands
| | - Famke L Schneiders
- Department of Medical Oncology; VU University Medical Center ; Amsterdam, The Netherlands
| | - Emmanuel Scotet
- Institut National de la Santé et de la Recherche Médicale; UMR892; Center de Recherche en Cancérologie Nantes-Angers ; Nantes Cedex, France
| | - Henk M W Verheul
- Department of Medical Oncology; VU University Medical Center ; Amsterdam, The Netherlands
| | - Tanja D de Gruijl
- Department of Medical Oncology; VU University Medical Center ; Amsterdam, The Netherlands
| | - Hans J van der Vliet
- Department of Medical Oncology; VU University Medical Center ; Amsterdam, The Netherlands
| |
Collapse
|
36
|
Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, Hennart B, Allorge D, van Geel N, Van Gele M, Brochez L. Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. Oncoimmunology 2015; 4:e982382. [PMID: 25949897 DOI: 10.4161/2162402x.2014.982382] [Citation(s) in RCA: 77] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2014] [Accepted: 10/28/2014] [Indexed: 12/20/2022] Open
Abstract
In melanoma, both the induction of immunosuppression by tumor cells and the inflammatory antitumor response can induce an upregulation of counter-regulatory mechanisms such as indoleamine 2,3-dioxygenase (IDO), programmed death-ligand 1 (PD-L1) and CTLA-4+ regulatory T-cells (Tregs) in the tumor microenvironment. Even though these immunosuppressive mediators are targets for immunotherapy, research investigating their expression in the peripheral blood is lacking. We therefore, performed flow cytometry on PBMCs of stage I-IV melanoma patients. IDO expression was detected in plasmacytoid dendritic cells (pDC) and monocytic myeloid-derived suppressor cells (mMDSC), and increased in advanced disease stage (p = 0.027). Tryptophan breakdown confirmed the functional activity of IDO and was linked with increased PD-L1+ cytotoxic T-cells (p = 0.009), relative lymphopenia (p = 0.036), and a higher mDC/pDC ratio (p = 0.002). High levels of circulating PD-L1+ cytotoxic T-cells were associated with increased CTLA-4 expression by Tregs (p = 0.005) and MDSC levels (p = 0.033). This illustrates that counter-regulatory immune mechanisms in melanoma should be considered as one interrelated signaling network. Moreover, both increased PD-L1+ T-cells and CTLA-4 expression in Tregs conferred a negative prognosis, indicating their in vivo relevance. Remarkably, circulating CTLA-4, IDO, and pDC levels were altered according to prior invasion of the sentinel lymph node and IDO expression in the sentinel was associated with more IDO+ PBMCs. We conclude that the expression of IDO, PD-L1, and CTLA-4 in the peripheral blood of melanoma patients is strongly interconnected, associated with advanced disease and negative outcome, independent of disease stage. Combination treatments targeting several of these markers are therefore likely to exert a synergistic response.
Collapse
Key Words
- AJCC
- American Joint Committee on Cancer system
- CC, correlation coefficientCTLA-4
- Cytotoxic T Lymphocyte-Associated Antigen 4
- DC, dendritic cells
- HR, hazard ratio
- IDO, indoleamine 2, 3-dioxygenase
- IFNγ, interferon-gamma
- IQR, interquartile range
- Kyn, kynurenine
- MDSC, myeloid-derived suppressor cells
- MFI, mean fluorescence intensity
- OS, overall survival
- PBMC, peripheral blood mononuclear cells
- PD-1, programmed cell death protein 1
- PD-L1, Programmed-Death Ligand 1
- Treg, regulatory T-cell
- Tryp, tryptophan
- UPLC, ultra-performance liquid chromatography
- cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)
- indoleamine 2-3-dioxygenase (IDO)
- mDC, myeloid DC
- mMDSC, monocytic MDSC
- melanoma
- negative feedback mechanism
- pDC, plasmacytoid DC
- pmnMDSC, polymorphonuclear MDSC
- prognosis
- programmed-death ligand 1 (PD-L1)
- regulatory T-cells
Collapse
Affiliation(s)
- I Chevolet
- Department of Dermatology; Ghent University Hospital Ghent, Belgium
| | - R Speeckaert
- Department of Dermatology; Ghent University Hospital Ghent, Belgium
| | - M Schreuer
- Department of Medical Oncology ; UZ-Brussel ; Brussels, Belgium ; Department of Medical Oncology; Ghent University Hospital ; Ghent, Belgium
| | - B Neyns
- Department of Medical Oncology ; UZ-Brussel ; Brussels, Belgium
| | - O Krysko
- Upper Airways Research Laboratory; Ghent University Hospital ; Ghent, Belgium
| | - C Bachert
- Upper Airways Research Laboratory; Ghent University Hospital ; Ghent, Belgium
| | - B Hennart
- Laboratoire de Toxicologie; CHU Lille ; Lille, France
| | - D Allorge
- Laboratoire de Toxicologie; CHU Lille ; Lille, France
| | - N van Geel
- Department of Dermatology; Ghent University Hospital Ghent, Belgium
| | - M Van Gele
- Department of Dermatology; Ghent University Hospital Ghent, Belgium
| | - L Brochez
- Department of Dermatology; Ghent University Hospital Ghent, Belgium
| |
Collapse
|
37
|
Vonka V, Humlova Z, Klamova H, Kujovska-Krcmova L, Petrackova M, Hamsikova E, Krmencikova-Fliegl M, Duskova M, Roth Z. Kynurenine and uric acid levels in chronic myeloid leukemia patients. Oncoimmunology 2015; 4:e992646. [PMID: 25949913 DOI: 10.4161/2162402x.2014.992646] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2014] [Accepted: 11/24/2014] [Indexed: 01/20/2023] Open
Abstract
Indoleamine 2,3-dioxygenase 1 (IDO1), IDO2 and tryptophan 2,3-dioxygenase (TDO) represent some of the key immune regulators. Their increased activity has been demonstrated in a number of human malignancies but not yet in chronic myeloid leukemia (CML). In the present study, the activity of these enzymes was tested in 29 CML patients and 28 healthy subjects by monitoring the kynurenine (KYN)/tryptophan ratio. Serum samples taken prior to the therapy displayed a highly significant difference in KYN levels between the patient and control groups. However, increased KYN levels were detected in only 13 (44.8%) of these CML patients. The KYN levels in pretreatment sera of the patients correlated with the tumor burden. There was also a strong correlation between KYN levels and uric acid levels (UA). This suggests but does not prove the possible involvement of UA in activating IDO family of enzymes. Whenever tested, the increased KYN levels normalized in the course of the therapy. Patients with normal KYN levels in their pretreatment sera and subsequently treated with interferon-α, showed a transitory increase in their KYN levels. The present data indicate that CML should be added to the malignancies with an increased activity of the IDO family of enzymes and suggest that IDO inhibitors may be used in the treatment of CML patients.
Collapse
Key Words
- 3-dioxygenase
- CML, chronic myeloid leukemia
- IDO, indoleamine 2, 3-dioxygenase
- INFα, interferon- α
- INFγ, interferon-γ
- KTI, kynurenine/tryptophan index
- KYN, kynurenine
- NK, natural killer
- PBMC, peripheral blood mononuclear cells
- Ph+, Philadelphia chromosome positive
- T regs, regulatory T cells
- TDO, tryptophan 2, 3-dioxygenase
- TKI, tyrosine-kinase inhibitors
- TRY, tryptophan
- UA, uric acid.
- chronic myeloid leukemia
- indoleamine 2
- kynurenine
- tryptophan metabolism
- uric acid
Collapse
Affiliation(s)
- Vladimir Vonka
- Department of Experimental Virology; Institute of Haematology and Blood Transfusion ; Prague, Czech Republic
| | - Zuzana Humlova
- Institute of Immunology; First Medical Faculty; Charles University ; Prague; Czech Republic ; Department of Immunology and Microbiology; 1st Medical Faculty; Charles University, and the General Teaching Hospital in Prague ; Prague, Czech Republic
| | - Hana Klamova
- Department of Experimental Virology; Institute of Haematology and Blood Transfusion ; Prague, Czech Republic
| | - Lenka Kujovska-Krcmova
- Department of Analytical Chemistry; Faculty of Pharmacy; Charles University ; Hradec Králové, Czech Republic ; III. Internal Gerontometabolic Clinic; University Hospital ; Hradec Králové, Czech Republic
| | - Martina Petrackova
- Department of Experimental Virology; Institute of Haematology and Blood Transfusion ; Prague, Czech Republic
| | - Eva Hamsikova
- Department of Experimental Virology; Institute of Haematology and Blood Transfusion ; Prague, Czech Republic
| | - Monika Krmencikova-Fliegl
- Department of Experimental Virology; Institute of Haematology and Blood Transfusion ; Prague, Czech Republic
| | - Martina Duskova
- Department of Experimental Virology; Institute of Haematology and Blood Transfusion ; Prague, Czech Republic
| | - Zdenek Roth
- Department of Biostatistics; State Institute of Health ; Prague, Czech Republic
| |
Collapse
|
38
|
Punt S, Langenhoff JM, Putter H, Fleuren GJ, Gorter A, Jordanova ES. The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review. Oncoimmunology 2015; 4:e984547. [PMID: 25949881 DOI: 10.4161/2162402x.2014.984547] [Citation(s) in RCA: 87] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2014] [Accepted: 10/31/2014] [Indexed: 12/22/2022] Open
Abstract
Both IL-17 and Th17 cells have been ascribed tumor promoting as well as tumor suppressing functions. We reviewed the literature on correlations between IL-17 versus Th17 cells and survival in human cancer, following the PRISMA guidelines. Serum, formalin-fixed, paraffin-embedded (FFPE) tissue and peripheral blood samples were most frequently studied. High IL-17 quantities were correlated with poor prognosis, whereas high Th17 cell frequencies were correlated with improved prognosis. Since Th17 cells are a subpopulation of IL-17+ cells and had a different correlation with prognosis than total IL-17, we substantiate that a distinction should be made between Th17 and other IL-17+ cells.
Collapse
Affiliation(s)
- Simone Punt
- Department of Pathology; Leiden University Medical Center ; Leiden, The Netherlands
| | | | - H Putter
- Department of Medical Statistics and Bioinformatics; Leiden University Medical Center ; Leiden, The Netherlands
| | - Gert Jan Fleuren
- Department of Pathology; Leiden University Medical Center ; Leiden, The Netherlands
| | - Arko Gorter
- Department of Pathology; Leiden University Medical Center ; Leiden, The Netherlands
| | | |
Collapse
|
39
|
Abstract
Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme. Remarkably, we discovered IDO-specific T cells that can influence adaptive immune reactions in patients with cancer. Further, a recent phase I clinical trial demonstrated long-lasting disease stabilization without toxicity in patients with non-small-cell lung cancer (NSCLC) who were vaccinated with an IDO-derived HLA-A2-restricted epitope.
Collapse
Affiliation(s)
- Mads Hald Andersen
- Department of Hematology; Center for Cancer Immune Therapy (CCIT); Copenhagen University Hospital ; Herlev, Denmark
| | - Inge Marie Svane
- Department of Hematology; Center for Cancer Immune Therapy (CCIT); Copenhagen University Hospital ; Herlev, Denmark ; Department of Oncology; Copenhagen University Hospital ; Herlev, Denmark
| |
Collapse
|
40
|
Goebel L, Grage-Griebenow E, Gorys A, Helm O, Genrich G, Lenk L, Wesch D, Ungefroren H, Freitag-Wolf S, Sipos B, Röcken C, Schäfer H, Sebens S. CD4 + T cells potently induce epithelial-mesenchymal-transition in premalignant and malignant pancreatic ductal epithelial cells-novel implications of CD4 + T cells in pancreatic cancer development. Oncoimmunology 2015; 4:e1000083. [PMID: 26137395 DOI: 10.1080/2162402x.2014.1000083] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2014] [Revised: 12/15/2014] [Accepted: 12/16/2014] [Indexed: 01/06/2023] Open
Abstract
Chronic pancreatitis (CP) is a risk factor of pancreatic ductal adenocarcinoma (PDAC) and characterized by a pronounced desmoplastic reaction with CD4+ T cells accounting for the majority of the stromal T cell infiltrate. Epithelial-mesenchymal-transition (EMT) is a critical process for metastasis by which epithelial/carcinoma cells become enabled to disseminate probably prior to tumor formation. To investigate whether CD4+ T cells induce EMT in human pancreatic ductal epithelial cells, premalignant H6c7 cells were mono- or co-cultured with human CD4+CD25+CD127-CD49d- regulatory T cells (T-regs) or CD4+CD25- T-effector cells (T-effs) being isolated by negative magnetic bead separation from blood of healthy donors. Particularly in the presence of activated T-effs, H6c7 cells acquired a spindle-shaped morphology, reduced E-cadherin expression, and elevated expression of the mesenchymal proteins vimentin, L1CAM, and ZEB-1. This was accompanied by an increased invasive behavior. Moreover, activated T-effs exerted similar effects in the PDAC cell line T3M4. Blocking of TNF-α and IL-6 being released at greater amounts into supernatants during co-cultures with activated T-effs attenuated the EMT-associated alterations in H6c7 cells. Supporting these findings, EMT-associated alterations (exemplified by reduced E-cadherin expression and enhanced expression of vimentin and L1CAM) were predominantly detected in ductal epithelium of CP tissues surrounded by a dense stroma enriched with CD4+ T cells. Overall this study points to a novel role of CD4+ T cells beyond their immune function in pancreatic tumorigenesis and underscores the view that EMT induction in pancreatic ductal epithelial cells represents an early event in PDAC development being essentially promoted by inflammatory processes.
Collapse
Affiliation(s)
- Lisa Goebel
- Group Inflammatory Carcinogenesis; Institute for Experimental Medicine; Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein (UKSH) Campus Kiel ; Kiel, Germany
| | - Evelin Grage-Griebenow
- Group Inflammatory Carcinogenesis; Institute for Experimental Medicine; Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein (UKSH) Campus Kiel ; Kiel, Germany
| | - Artur Gorys
- Group Inflammatory Carcinogenesis; Institute for Experimental Medicine; Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein (UKSH) Campus Kiel ; Kiel, Germany
| | - Ole Helm
- Group Inflammatory Carcinogenesis; Institute for Experimental Medicine; Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein (UKSH) Campus Kiel ; Kiel, Germany
| | - Geeske Genrich
- Group Inflammatory Carcinogenesis; Institute for Experimental Medicine; Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein (UKSH) Campus Kiel ; Kiel, Germany
| | - Lennart Lenk
- Group Inflammatory Carcinogenesis; Institute for Experimental Medicine; Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein (UKSH) Campus Kiel ; Kiel, Germany
| | - Daniela Wesch
- Institute of Immunology; Christian-Albrechts-University and UKSH Campus Kiel ; Kiel, Germany
| | | | - Sandra Freitag-Wolf
- Institute of Medical Informatics and Statistics; UKSH Campus Kiel ; Kiel, Germany
| | - Bence Sipos
- Department of Pathology and Neuropathology; University Hospital Tübingen ; Tübingen, Germany
| | | | - Heiner Schäfer
- Laboratory of Molecular Gastroenterology & Hepatology; Department of Internal Medicine I; UKSH Campus Kiel ; Kiel, Germany
| | - Susanne Sebens
- Group Inflammatory Carcinogenesis; Institute for Experimental Medicine; Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein (UKSH) Campus Kiel ; Kiel, Germany
| |
Collapse
|
41
|
Islam MA, Hooiveld GJEJ, van den Berg JHJ, Boekschoten MV, van der Velpen V, Murk AJ, Rietjens IMCM, van Leeuwen FXR. Plasma bioavailability and changes in PBMC gene expression after treatment of ovariectomized rats with a commercial soy supplement. Toxicol Rep 2015; 2:308-321. [PMID: 28962364 PMCID: PMC5598277 DOI: 10.1016/j.toxrep.2014.12.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2014] [Revised: 12/18/2014] [Accepted: 12/18/2014] [Indexed: 11/02/2022] Open
Abstract
The health effects of soy supplementation in (post)menopausal women are still a controversial issue. The aim of the present study was to establish the effect of the soy isoflavones (SIF) present in a commercially available supplement on ovariectomized rats and to investigate whether these rats would provide an adequate model to predict effects of SIF in (post)menopausal women. Two dose levels (i.e. 2 and 20 mg/kg b.w.) were used to characterize plasma bioavailability, urinary and fecal concentrations of SIF and changes in gene expression in peripheral blood mononuclear cells (PBMC). Animals were dosed at 0 and 48 h and sacrificed 4 h after the last dose. A clear dose dependent increase of SIF concentrations in plasma, urine and feces was observed, together with a strong correlation in changes in gene expression between the two dose groups. All estrogen responsive genes and related biological pathways (BPs) that were affected by the SIF treatment were regulated in both dose groups in the same direction and indicate beneficial effects. However, in general no correlation was found between the changes in gene expression in rat PBMC with those in PBMC of (post)menopausal women exposed to a comparable dose of the same supplement. The outcome of this short-term study in rats indicates that the rat might not be a suitable model to predict effects of SIF in humans. Although the relative exposure period in this rat study is comparable with that of the human study, longer repetitive administration of rats to SIF may be required to draw a final conclusion on the suitability of the rat a model to predict effects of SIF in humans.
Collapse
Key Words
- BPs, biological pathways
- Bioavailability
- DMSO, dimethyl sulfoxide
- Dose effect
- E2, estradiol
- ECM, extracellular matrix
- EREs, estrogen-responsive elements
- ERs, estrogen receptors
- GSEA, gene set enrichment analysis
- Gene expression
- HD, high dose
- HPLC, high performance liquid chromatography
- KEGG, kyoto encyclopedia of genes and genomes
- LD, low dose
- MDS, multidimensional scaling
- NCBI, National Center for Biotechnology Information
- PBMC, peripheral blood mononuclear cells
- SIF, soy isoflavones
- Soy supplementation
- Species differences
- UPC, universal expression code
Collapse
Affiliation(s)
- Mohammed A Islam
- Division of Toxicology, Wageningen University, Tuinlaan 5, 6703 HE Wageningen, The Netherlands
| | - Guido J E J Hooiveld
- Division of Human Nutrition, Wageningen University, Bomenweg 2, 6703 HE Wageningen, The Netherlands
| | | | - Mark V Boekschoten
- Division of Human Nutrition, Wageningen University, Bomenweg 2, 6703 HE Wageningen, The Netherlands
| | - Vera van der Velpen
- Division of Human Nutrition, Wageningen University, Bomenweg 2, 6703 HE Wageningen, The Netherlands.,Department of Nutrition, Norwich Medical School, University of East Anglia, Norwich, UK
| | - Albertinka J Murk
- Division of Toxicology, Wageningen University, Tuinlaan 5, 6703 HE Wageningen, The Netherlands
| | - Ivonne M C M Rietjens
- Division of Toxicology, Wageningen University, Tuinlaan 5, 6703 HE Wageningen, The Netherlands
| | - F X Rolaf van Leeuwen
- Division of Toxicology, Wageningen University, Tuinlaan 5, 6703 HE Wageningen, The Netherlands
| |
Collapse
|
42
|
Overdijk MB, Verploegen S, Bögels M, van Egmond M, van Bueren JJL, Mutis T, Groen RWJ, Breij E, Martens ACM, Bleeker WK, Parren PWHI. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 2015; 7:311-21. [PMID: 25760767 PMCID: PMC4622648 DOI: 10.1080/19420862.2015.1007813] [Citation(s) in RCA: 374] [Impact Index Per Article: 41.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2014] [Revised: 11/14/2014] [Accepted: 12/01/2014] [Indexed: 01/14/2023] Open
Abstract
Daratumumab (DARA) is a human CD38-specific IgG1 antibody that is in clinical development for the treatment of multiple myeloma (MM). The potential for IgG1 antibodies to induce macrophage-mediated phagocytosis, in combination with the known presence of macrophages in the tumor microenvironment in MM and other hematological tumors, led us to investigate the contribution of antibody-dependent, macrophage-mediated phagocytosis to DARA's mechanism of action. Live cell imaging revealed that DARA efficiently induced macrophage-mediated phagocytosis, in which individual macrophages rapidly and sequentially engulfed multiple tumor cells. DARA-dependent phagocytosis by mouse and human macrophages was also observed in an in vitro flow cytometry assay, using a range of MM and Burkitt's lymphoma cell lines. Phagocytosis contributed to DARA's anti-tumor activity in vivo, in both a subcutaneous and an intravenous leukemic xenograft mouse model. Finally, DARA was shown to induce macrophage-mediated phagocytosis of MM cells isolated from 11 of 12 MM patients that showed variable levels of CD38 expression. In summary, we demonstrate that phagocytosis is a fast, potent and clinically relevant mechanism of action that may contribute to the therapeutic activity of DARA in multiple myeloma and potentially other hematological tumors.
Collapse
Key Words
- ADCC, antibody-dependent cellular cytotoxicity
- BL, Burkitt's lymphoma
- BM, bone marrow
- Burkitt's lymphoma
- CCS, cosmic calf serum
- CD38
- CDC, complement-dependent cytotoxicity
- DARA, daratumumab
- DP, double positive
- E:T, effector to target ratio
- FcγR, Fc-gamma receptor
- IMiD, immunomodulatory drug
- MM, multiple myeloma
- MNC, mononuclear cells
- Mϕ, macrophage
- PBMC, peripheral blood mononuclear cells
- daratumumab
- mAb, monoclonal antibody
- macrophage
- multiple myeloma
- phagocytosis
- therapeutic antibody
Collapse
Affiliation(s)
| | | | - Marijn Bögels
- Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
- Department of Surgery; VU University Medical Center; Amsterdam, The Netherlands
| | - Marjolein van Egmond
- Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
- Department of Surgery; VU University Medical Center; Amsterdam, The Netherlands
| | | | - Tuna Mutis
- Department of Clinical Chemistry and Hematology; University Medical Center; Utrecht, The Netherlands
| | - Richard WJ Groen
- Department of Cell Biology; University Medical Center; Utrecht, The Netherlands
| | | | - Anton CM Martens
- Department of Cell Biology; University Medical Center; Utrecht, The Netherlands
- Department of Immunology; University Medical Center; Utrecht, The Netherlands
| | | | - Paul WHI Parren
- Genmab; Utrecht, The Netherlands
- Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
- Department of Immunohematology and Blood Transfusion; Leiden University Medical Center; Leiden, The Netherlands
| |
Collapse
|
43
|
Spary LK, Salimu J, Webber JP, Clayton A, Mason MD, Tabi Z. Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14 + PD-L1 + phenotype in prostate cancer. Oncoimmunology 2014; 3:e955331. [PMID: 25941611 DOI: 10.4161/21624011.2014.955331] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2014] [Accepted: 07/25/2014] [Indexed: 12/31/2022] Open
Abstract
Tumor-associated stromal myofibroblasts are essential for the progression and metastatic spread of solid tumors. Corresponding myeloid cell infiltration into primary tumors is a negative prognostic factor in some malignancies. The aim of this study was to define the exact role of stromal myofibroblasts and stromal factors in early prostate carcinoma (PCa) regulating monocyte infiltration and differentiation into dendritic cells (DCs). Epithelial and stromal primary cultures were generated from PCa biopsies and their purity confirmed. Stromal cells produced significantly more of the (C-C) motif chemokine ligand 2 (CCL2), interleukin 6 (IL-6) and transforming growth factor β (TGFβ) than epithelial cells. Monocyte chemoattraction was predominantly due to stromal-derived factors, mainly CCL2. DCs generated in the presence of stromal (but not epithelial) factors upregulated CD209, but failed to downregulate the monocyte marker CD14 in a signal transducer and activator of transcription 3 (STAT3)-dependent manner. Monocytes exposed to stromal factors did not produce detectable amounts of IL-10, however, upon lipopolysaccharide stimulation, stromal factor generated dendritic cells (sDC) produced significantly more IL-10 and less IL-12 than their conventional DC counterparts. sDC failed to cross-present tumor-antigen to CD8+ T cells and suppressed T-cell proliferation. Most importantly, sDC expressed significantly elevated levels of programmed cell death ligand-1 (PD-L1) in a primarily STAT3 and IL-6-dependent manner. In parallel with our findings in vitro, tumor-infiltrating CD14+ cells in situ were found to express both PD-L1 and CD209, and a higher percentage of tumor-associated CD3+ T cells expressed programmed cell death-1 (PD-1) molecules compared to T cells in blood. These results demonstrate a hitherto undescribed, fundamental contribution of tumor-associated stromal myofibroblasts to the development of an immunosuppressive microenvironment in early PCa.
Collapse
Key Words
- CCL2
- CCL2, (C–C) motif chemokine ligand-2
- CFSE, carboxyfluorescein succinimidyl ester
- CK, cytokeratin
- CM, conditioned media
- CXCL, chemokine (C–X–C) motif
- DC, dendritic cell
- ELISA, enzyme-linked immunosorbent assay
- GM-CSF, granulocyte macrophage colony-stimulating factor
- HFF, human foreskin fibroblast
- HGF, hepatocyte growth factor
- I-TAC, interferon-inducible T cell α chemoattractant
- IFN, interferon
- IL, interleukin
- IL-6
- IP-10, interferon-γ induced protein 10
- LPS, lipopolysaccharide
- MIF, macrophage inhibitory factor
- PBMC, peripheral blood mononuclear cells
- PCaEp, prostate cancer epithelia
- PCaSt, prostate cancer stroma
- PD-1, programmed cell death-1
- PD-L1
- PD-L1, programmed cell death ligand-1
- RANTES/CCL5, regulated on activation, normal T cell expressed and secreted
- SCBM, stromal cell basal media
- SDF-1, stromal-derived factor-1
- STAT3
- STAT3, signal transducer and activator of transcription 3
- TGFβ, transforming growth factor β
- TIL, tumor infiltrating leukocytes
- VEGF, vascular endothelial growth factor
- antigen cross-presentation
- dendritic cells
- immunosuppression
- prostate cancer
- sDC, DC generated in the presence of 50% PCaSt-CM
- tumor microenvironment
- tumor stroma
- α-SMA, α-smooth muscle actin
Collapse
Affiliation(s)
- Lisa K Spary
- Institute of Cancer and Genetics; School of Medicine ; Cardiff University ; Whitchurch, Cardiff, UK
| | - Josephine Salimu
- Institute of Cancer and Genetics; School of Medicine ; Cardiff University ; Whitchurch, Cardiff, UK
| | - Jason P Webber
- Institute of Cancer and Genetics; School of Medicine ; Cardiff University ; Whitchurch, Cardiff, UK
| | - Aled Clayton
- Institute of Cancer and Genetics; School of Medicine ; Cardiff University ; Whitchurch, Cardiff, UK
| | - Malcolm D Mason
- Institute of Cancer and Genetics; School of Medicine ; Cardiff University ; Whitchurch, Cardiff, UK
| | - Zsuzsanna Tabi
- Institute of Cancer and Genetics; School of Medicine ; Cardiff University ; Whitchurch, Cardiff, UK
| |
Collapse
|
44
|
Winiarska M, Bojarczuk K, Pyrzynska B, Bil J, Siernicka M, Dwojak M, Bobrowicz M, Miazek N, Zapala P, Zagozdzon A, Krol M, Syta A, Podszywalow-Bartnicka P, Pilch Z, Dabrowska-Iwanicka A, Juszczynski P, Efremov DG, Slabicki M, Zenz T, Le Roy A, Olive D, Rygiel TP, Leusen JHW, Golab J. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. MAbs 2014; 6:1300-13. [PMID: 25517315 PMCID: PMC4622538 DOI: 10.4161/mabs.32106] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Clinical trials with SRC family kinases (SFKs) inhibitors used alone or in a combination with anti-CD20 monoclonal antibodies (mAbs) are currently underway in the treatment of B-cell tumors. However, molecular interactions between these therapeutics have not been studied so far. A transcriptional profiling of tumor cells incubated with SFKs inhibitors revealed strong downregulation of MS4A1 gene encoding CD20 antigen. In a panel of primary and established B-cell tumors we observed that SFKs inhibitors strongly affect CD20 expression at the transcriptional level, leading to inhibition of anti-CD20 mAbs binding and increased resistance of tumor cells to complement-dependent cytotoxicity. Activation of the AKT signaling pathway significantly protected cells from dasatinib-triggered CD20 downregulation. Additionally, SFKs inhibitors suppressed antibody-dependent cell-mediated cytotoxicity by direct inhibition of natural killer cells. Abrogation of antitumor activity of rituximab was also observed in vivo in a mouse model. Noteworthy, the effects of SFKs inhibitors on NK cell function are largely reversible. The results of our studies indicate that development of optimal combinations of novel treatment modalities with anti-CD20 mAbs should be preceded by detailed preclinical evaluation of their effects on target cells.
Collapse
Affiliation(s)
- Magdalena Winiarska
- a Department of Immunology; Center for Biostructure Research ; Medical University of Warsaw ; Warsaw , Poland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Thaventhiran T, Alhumeed N, Yeang HXA, Sethu S, Downey JS, Alghanem AF, Olayanju A, Smith EL, Cross MJ, Webb SD, Williams DP, Bristow A, Ball C, Stebbings R, Sathish JG. Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist. MAbs 2014; 6:1290-9. [PMID: 25517314 PMCID: PMC4622985 DOI: 10.4161/mabs.29758] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
The CD28 superagonist (CD28SA) TGN1412 was administered to humans as an agent that can selectively activate and expand regulatory T cells but resulted in uncontrolled T cell activation accompanied by cytokine storm. The molecular mechanisms that underlie this uncontrolled T cell activation are unclear. Physiological activation of T cells leads to upregulation of not only activation molecules but also inhibitory receptors such as PD-1. We hypothesized that the uncontrolled activation of CD28SA-stimulated T cells is due to both the enhanced expression of activation molecules and the lack of or reduced inhibitory signals. In this study, we show that anti-CD3 antibody-stimulated human T cells undergo time-limited controlled DNA synthesis, proliferation and interleukin-2 secretion, accompanied by PD-1 expression. In contrast, CD28SA-activated T cells demonstrate uncontrolled activation parameters including enhanced expression of LFA-1 and CCR5 but fail to express PD-1 on the cell surface. We demonstrate the functional relevance of the lack of PD-1 mediated regulatory mechanism in CD28SA-stimulated T cells. Our findings provide a molecular explanation for the dysregulated activation of CD28SA-stimulated T cells and also highlight the potential for the use of differential expression of PD-1 as a biomarker of safety for T cell immunostimulatory biologics.
Collapse
Key Words
- APC, antigen presenting cell
- CCR5, C-C chemokine receptor type 5
- CD28 superagonist
- CD28SA, CD28 superagonist
- CK2, casein kinase 2
- CTLA-4, cytotoxic T-Lymphocyte Antigen 4
- IFNγ, interferon gamma
- IL-2, interleukin 2
- LAG-3, Lymphocyte-activation gene 3
- LFA-1, lymphocyte function-associated antigen 1
- MFI, mean fluorescence intensity
- PBMC, peripheral blood mononuclear cells
- PD-1
- PD-1, programmed cell death protein 1
- PD-L1, programmed cell death-ligand 1
- PTEN, phosphatase and tensin homolog
- S-phase, synthesis phase
- T cells
- TCR, T cell receptor
- TEMs, effector memory T cells
- TGN1412
- TIM-3, T cell immunoglobulin mucin 3
- immunostimulatory biologics
Collapse
Affiliation(s)
- Thilipan Thaventhiran
- a Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology ; University of Liverpool ; Liverpool , UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
Signal peptide (SP) domains have a common motif but also sequence specific features. This knowledge was mainly ignored by immunologists who considered SP as generic, short-lived, targeting sequences. Consequently, while SP-derived MHC class I, class II and HLA-E epitopes have been isolated, their use as antigen-specific vaccine candidates (VCs) was mostly neglected. Recently we demonstrated the rational of selecting entire SP domains as multi-epitope long peptide VCs based on their high T and B-cell epitope densities. This review summarizes preclinical and clinical results demonstrating the various advantages of human SP domain VCs derived from both bacterial and tumor antigens. Such vaccine design provides for a straightforward, yet unique immunotherapeutic means of generating robust, non-toxic, diversified, combined antigen-specific CD4+/CD8+ T/B-cell immunity, irrespective of patient HLA repertoire also in disease associated transporter-associated with antigen processing (TAP) deficiencies. Subsequent clinical trials will further assess the full potential of this approach.
Collapse
Key Words
- ADCC, antibody-dependent cell-mediated cytotoxicity
- AE, adverse events
- APC, antigen presenting cells
- DC, dendritic cells
- ER, endoplasmic reticulum
- ImMucin
- LP, long peptide
- MHC
- MHC, major histocompatibility complex
- MM, multiple myeloma
- MUC1
- PBMC, peripheral blood mononuclear cells
- SP, signal peptide
- SPP, signal peptide peptidase
- SPase, signal peptidase
- T-cell
- TAA, tumor associated antigen
- TAP, transporter-associated with antigen processing
- VC, vaccine candidate
- antibodies
- cancer
- hGM-CSF, human granulocyte-macrophage colony-stimulating factor
- long peptide
- signal peptide
- tuberculosis
- vaccine
Collapse
|
47
|
Feldthusen AD, Larsen J, Pedersen PL, Toft Kristensen T, Kvetny J. Pregnancy-induced alterations in mitochondrial function in euthyroid pregnant women and pregnant women with subclinical hypothyroidism; relation to adverse outcome. J Clin Transl Endocrinol 2013; 1:e13-e17. [PMID: 29235583 PMCID: PMC5684968 DOI: 10.1016/j.jcte.2013.12.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/21/2013] [Revised: 11/25/2013] [Accepted: 12/16/2013] [Indexed: 12/01/2022]
Abstract
Background It is well documented that overt hypothyroidism is associated with adverse pregnancy outcomes, but studies of subclinical hypothyroidism have demonstrated conflicting results. Objective Thyroid hormones are known to regulate mitochondrial function, and the aim of this study was to examine the possible relationship of subclinical hypothyroidism and mitochondrial dysfunction to adverse pregnancy outcomes in pregnant women. Methods Women in their third trimester of pregnancy (n = 113) who did not receive thyroid medication were included in this cross-sectional study. All participants were interviewed, and their thyroid status was determined. All participants had concentrations of thyroid hormones (fT4 and tT3) within the reference range. In addition to thyroid status, mitochondrial membrane potential (MMP) and reactive oxygen species (ROS) were measured by flow cytometry. To establish a reference range of MMP and ROS, a group of euthyroid, nonpregnant women were used as euthyroid controls. Adverse pregnancy outcome was defined as preterm delivery, preeclampsia, placental abruption, Apgar score <7 points 1 minute after birth, or postpartum hemorrhage. Results The prevalence of subclinical hypothyroidism among pregnant women was 17% (n = 19), and the number of overall adverse pregnancy outcomes was increased (p = 0.02) compared with that in euthyroid pregnant women. Preeclampsia, poor Apgar score, and postpartum hemorrhage were more frequent in the subclinical hypothyroidism group than in the euthyroid group (p = 0.04, p = 0.001 and p = 0.03, respectively), and more women showed prolonged gestation and gave birth later than 41 weeks of gestation than in the euthyroid group (p = 0.04). Compared with euthyroid, nonpregnant controls, a physiological upregulation of mitochondrial function was observed in euthyroid pregnant women. This was impaired in pregnant women with subclinical hypothyroidism. Compared with euthyroid, nonpregnant controls, pregnant women had increased ROS regardless of their thyroid status. Conclusion We speculate that the unfavorable effects on mitochondrial function in women with subclinical hypothyroidism may be associated with higher prevalence of adverse pregnancy outcomes.
Collapse
Key Words
- BMI, body mass index
- GA, gestational age
- MMP, mitochondrial membrane potential
- Mitochondrial dysfunction
- Mitochondrial membrane potential
- PBMC, peripheral blood mononuclear cells
- Pregnancy outcome
- ROS, reactive oxygen species
- Reactive oxygen species
- Subclinical hypothyroidism
- TMRM, tetramethylrhodamine methyl ester
- TPOAb, thyroid peroxidase antibody
- TSH, thyroid-stimulating hormone
- carboxy-H2DCFDA, 5(6)-carboxy-2'-7'-dichlorodihydrofluoresceindiacetate
- fT4, free thyroxine
- tT3, total triiodothyronine
Collapse
Affiliation(s)
- Anne-Dorthe Feldthusen
- Department of Obstetrics & Gynaecology, Naestved Hospital, Ringstedgade 61, 4700 Naestved, Denmark.,The Mitochondrial Research Unit, Naestved Hospital, Ringstedgade 61, 4700 Naestved, Denmark.,Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen N., Denmark
| | - Jacob Larsen
- The Mitochondrial Research Unit, Naestved Hospital, Ringstedgade 61, 4700 Naestved, Denmark.,Department of Clinical Pathology, Naestved Hospital, Ringstedgade 61, 4700 Naestved, Denmark
| | - Palle L Pedersen
- The Mitochondrial Research Unit, Naestved Hospital, Ringstedgade 61, 4700 Naestved, Denmark.,Department of Clinical Biochemistry, Naestved Hospital, Ringstedgade 61, 4700 Naestved, Denmark
| | - Tina Toft Kristensen
- The Mitochondrial Research Unit, Naestved Hospital, Ringstedgade 61, 4700 Naestved, Denmark.,Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen N., Denmark.,Department of Otorhinolaryngology - Head and Neck Surgery, Koege Hospital, Lykkebaekvej 1, 4600 Koege, Denmark
| | - Jan Kvetny
- The Mitochondrial Research Unit, Naestved Hospital, Ringstedgade 61, 4700 Naestved, Denmark.,Department of Internal Medicine, Naestved Hospital, Ringstedgade 61, 4700 Naestved, Denmark.,Institute of Regional Health Services, University of Southern Denmark, Denmark
| |
Collapse
|
48
|
Keane FM, Yao TW, Seelk S, Gall MG, Chowdhury S, Poplawski SE, Lai JH, Li Y, Wu W, Farrell P, Vieira de Ribeiro AJ, Osborne B, Yu DMT, Seth D, Rahman K, Haber P, Topaloglu AK, Wang C, Thomson S, Hennessy A, Prins J, Twigg SM, McLennan SV, McCaughan GW, Bachovchin WW, Gorrell MD. Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio 2013; 4:43-54. [PMID: 24371721 PMCID: PMC3871272 DOI: 10.1016/j.fob.2013.12.001] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Revised: 12/04/2013] [Accepted: 12/04/2013] [Indexed: 02/08/2023] Open
Abstract
The protease fibroblast activation protein (FAP) is a specific marker of activated mesenchymal cells in tumour stroma and fibrotic liver. A specific, reliable FAP enzyme assay has been lacking. FAP's unique and restricted cleavage of the post proline bond was exploited to generate a new specific substrate to quantify FAP enzyme activity. This sensitive assay detected no FAP activity in any tissue or fluid of FAP gene knockout mice, thus confirming assay specificity. Circulating FAP activity was ∼20- and 1.3-fold less in baboon than in mouse and human plasma, respectively. Serum and plasma contained comparable FAP activity. In mice, the highest levels of FAP activity were in uterus, pancreas, submaxillary gland and skin, whereas the lowest levels were in brain, prostate, leukocytes and testis. Baboon organs high in FAP activity included skin, epididymis, bladder, colon, adipose tissue, nerve and tongue. FAP activity was greatly elevated in tumours and associated lymph nodes and in fungal-infected skin of unhealthy baboons. FAP activity was 14- to 18-fold greater in cirrhotic than in non-diseased human liver, and circulating FAP activity was almost doubled in alcoholic cirrhosis. Parallel DPP4 measurements concorded with the literature, except for the novel finding of high DPP4 activity in bile. The new FAP enzyme assay is the first to be thoroughly characterised and shows that FAP activity is measurable in most organs and at high levels in some. This new assay is a robust tool for specific quantitation of FAP enzyme activity in both preclinical and clinical samples, particularly liver fibrosis. A novel synthetic fluorogenic substrate is proven to be FAP-specific. Mice have higher levels of circulating FAP activity compared to baboons or humans. No FAP activity was detected in urine or bile but bile contained high DPP4 activity. FAP activity is greatest in pancreas, uterus, salivary gland, skin and lymph node. FAP activity and protein is elevated in both serum and liver in human liver disease.
Collapse
Key Words
- ALD, alcoholic liver disease
- AMC, amino-4-methylcoumarin
- Biomarker
- DMSO, dimethyl sulfoxide
- DPP4, dipeptidyl peptidase 4
- Dipeptidyl peptidase
- EDTA, ethylene diamine tetra acetic acid
- FAP, fibroblast activation protein-α
- Fibroblast
- Fibrosis
- HCV, hepatitis C virus
- LDS, lithium dodecyl sulphate
- LN, lymph node
- Liver disease
- ND, non-diseased
- PBC, primary biliary cirrhosis
- PBMC, peripheral blood mononuclear cells
- PBS, phosphate-buffered saline
- PEP, prolyl endopeptidase
- PVDF, polyvinylidene fluoride
- Protease activity
- Protease substrates
- STLV, simian T-cell lymphotrophic virus
- gko, gene knock out
- het, heterozygous
- mAb, monoclonal antibody
- wt, wild type
- yrs, years
Collapse
Affiliation(s)
- Fiona M Keane
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | - Tsun-Wen Yao
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | | | - Margaret G Gall
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | - Sumaiya Chowdhury
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | - Sarah E Poplawski
- Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA
| | - Jack H Lai
- Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA
| | - Youhua Li
- Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA
| | - Wengen Wu
- Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA
| | - Penny Farrell
- Department of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Ana Julia Vieira de Ribeiro
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | - Brenna Osborne
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | - Denise M T Yu
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | - Devanshi Seth
- Centenary Institute, Camperdown, NSW, Australia ; Drug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Khairunnessa Rahman
- Drug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Paul Haber
- Sydney Medical School, University of Sydney, NSW, Australia ; Drug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - A Kemal Topaloglu
- Pediatric Endocrinology, Faculty of Medicine, Cukurova University, Adana, Turkey
| | - Chuanmin Wang
- Sydney Medical School, University of Sydney, NSW, Australia ; Collaborative Transplantation Research Group, Bosch Institute, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Sally Thomson
- Sydney Medical School, University of Sydney, NSW, Australia ; Department of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Annemarie Hennessy
- Department of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia ; School of Medicine, University of Western Sydney, NSW, Australia
| | - John Prins
- Mater Medical Research Institute, University of Queensland, and Department of Endocrinology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - Stephen M Twigg
- Sydney Medical School, University of Sydney, NSW, Australia ; Department of Endocrinology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Susan V McLennan
- Sydney Medical School, University of Sydney, NSW, Australia ; Department of Endocrinology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Geoffrey W McCaughan
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | - William W Bachovchin
- Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA
| | - Mark D Gorrell
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| |
Collapse
|
49
|
Hirose Y, Yamamoto Y, Yoshikai Y, Murosaki S. Oral intake of heat-killed Lactobacillus plantarum L-137 decreases the incidence of upper respiratory tract infection in healthy subjects with high levels of psychological stress. J Nutr Sci 2013; 2:e39. [PMID: 25191589 DOI: 10.1017/jns.2013.35] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2013] [Revised: 09/06/2013] [Accepted: 10/16/2013] [Indexed: 02/02/2023] Open
Abstract
The immunomodulatory effects of live or non-viable lactic acid bacteria have been extensively investigated. We reported that oral intake of heat-killed Lactobacillus plantarum L-137 (HK L-137) augmented innate and acquired immunity in mice and human subjects. To examine the effects of HK L-137 intake on upper respiratory tract infection (URTI) symptoms and immune functions in human subjects, a randomised, double-blind, placebo-controlled, parallel study was conducted in subjects with high psychological stress levels. A total of seventy-eight healthy subjects (thirty-three men and forty-five women; mean age 50·6 years) with scores of >41 on eighteen-item subscales of psychological distress in the Brief Job Stress Questionnaire were randomly assigned to receive a tablet containing HK L-137 (10 mg) or a placebo tablet daily for 12 weeks. The URTI symptoms were rated once daily on the validated twenty-one-item Wisconsin Upper Respiratory Symptom Survey-21. Immune functions, such as concanavalin A-induced proliferation and percentages of interferon (IFN)-γ- and IL-4-producing CD4 T cells of peripheral blood mononuclear cells (PBMC), and serum IFN-β concentrations were measured every 4 weeks. URTI incidence was significantly lower in the HK L-137 group than in the control group. URTI incidence, duration and severity, and duration of medication showed significant negative correlations with duration of HK L-137 intake. The percentage change from baseline of concanavalin A-induced proliferation of PBMC was significantly greater in the HK L-137 group than in the control group. These findings suggest that daily HK L-137 intake can decrease URTI incidence in healthy subjects, possibly through augmentation of immune functions.
Collapse
|
50
|
Temml V, Kuehnl S, Schuster D, Schwaiger S, Stuppner H, Fuchs D. Interaction of Carthamus tinctorius lignan arctigenin with the binding site of tryptophan-degrading enzyme indoleamine 2,3-dioxygenase. FEBS Open Bio 2013; 3:450-2. [PMID: 24251110 PMCID: PMC3829989 DOI: 10.1016/j.fob.2013.08.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2013] [Revised: 08/25/2013] [Accepted: 08/31/2013] [Indexed: 11/16/2022] Open
Abstract
Mediterranean Carthamus tinctorius (Safflower) is used for treatment of inflammatory conditions and neuropsychiatric disorders. Recently C. tinctorius lignans arctigenin and trachelogenin but not matairesinol were described to interfere with the activity of tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) in peripheral blood mononuclear cells in vitro. We examined a potential direct influence of compounds on IDO enzyme activity applying computational calculations based on 3D geometry of the compounds. The interaction pattern analysis and force field-based minimization was performed within LigandScout 3.03, the docking simulation with MOE 2011.10 using the X-ray crystal structure of IDO. Results confirm the possibility of an intense interaction of arctigenin and trachelogenin with the binding site of the enzyme, while matairesinol had no such effect.
Collapse
Key Words
- 1-MT, d-1-methyl tryptophan
- 5-HT, 5-hydroxytryptamine, serotonin
- Carthamus tinctorius
- GBVI/WSA, generalized-born volume integral/weighted surface area
- IDO, indoleamine 2,3-dioxygenase
- IFN-γ, interferon-γ
- Indoleamine-2,3-dioxygenase
- Kyn/Trp, kynurenine to tryptophan ratio
- Lignan
- MMFF94, Merck Molecular Force Field 94
- PBMC, peripheral blood mononuclear cells
- TDO, tryptophan 2,3-dioxygenase
- Treg, regulatory T-cells
Collapse
Affiliation(s)
- Veronika Temml
- University of Innsbruck, Institute of Pharmacy/Pharmacognosy, CCB Innrain 80/82, Innsbruck 6020, Austria
| | | | | | | | | | | |
Collapse
|